

# Deepak L Bhatt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3007388/publications.pdf>

Version: 2024-02-01

1,229  
papers

114,537  
citations

268

141  
h-index

232

305  
g-index

1257  
all docs

1257  
docs citations

1257  
times ranked

60346  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
3	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
4	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	27.0	3,017
5	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
6	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
7	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 2019, 380, 11-22.	27.0	2,153
8	Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine, 2012, 366, 1567-1576.	27.0	1,973
9	Bariatric Surgery versus Intensive Medical Therapy for Diabetes – 5-Year Outcomes. New England Journal of Medicine, 2017, 376, 641-651.	27.0	1,963
10	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	13.7	1,958
11	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	27.0	1,848
12	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
13	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19.	27.0	1,681
14	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
15	Bariatric Surgery versus Intensive Medical Therapy for Diabetes – 3-Year Outcomes. New England Journal of Medicine, 2014, 370, 2002-2013.	27.0	1,369
16	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	7.4	1,353
17	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2007, 297, 1197.	7.4	1,162
18	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	27.0	1,099

#	ARTICLE	IF	CITATIONS
19	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
20	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology, 2010, 56, 919-933.	2.8	1,058
21	Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 2010, 363, 1909-1917.	27.0	1,019
22	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
23	Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. New England Journal of Medicine, 2015, 373, 2015-2024.	27.0	874
24	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, The, 2017, 389, 1025-1034.	13.7	840
25	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	2.8	807
26	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
27	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
28	Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet, The, 2017, 389, 2383-2392.	13.7	718
29	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	27.0	695
30	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
31	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
32	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine, 2022, 386, 316-326.	27.0	640
33	Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA - Journal of the American Medical Association, 2010, 304, 1350.	7.4	626
34	Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e367-e386.	1.6	602
35	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation, 2014, 130, 1579-1588.	1.6	594
36	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation, 2008, 118, 1894-1909.	1.6	563

#	ARTICLE	IF	CITATIONS
37	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	27.0	560
38	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine, 2009, 361, 2318-2329.	27.0	533
39	Utilization of Early Invasive Management Strategies for High-Risk Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 2096.	7.4	525
40	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
41	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA - Journal of the American Medical Association, 2013, 310, 2510-22.	7.4	513
42	Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke. Circulation, 2011, 123, 750-758.	1.6	510
43	Effects of<i>CYP2C19</i>Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine, 2010, 363, 1704-1714.	27.0	497
44	Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 1319-1325.	2.8	496
45	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€“TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	11.4	482
46	Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JAMA - Journal of the American Medical Association, 2014, 311, 1632.	7.4	469
47	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
48	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	2.2	458
49	Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 312, 1754.	7.4	430
50	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Circulation, 2009, 119, 2877-2885.	1.6	428
51	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
52	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
53	Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. New England Journal of Medicine, 2019, 381, 243-251.	27.0	408
54	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. New England Journal of Medicine, 2018, 378, 603-614.	27.0	399

#	ARTICLE	IF	CITATIONS
55	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. Circulation, 2015, 132, 923-931.	1.6	397
56	Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation, 2019, 139, 1047-1056.	1.6	393
57	ACC/AHA/ASA 2011 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2011, 57, 1502-1517.	2.8	390
58	β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	7.4	377
59	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 2002, 90, 625-628.	1.6	376
60	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
61	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y <sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
62	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. American Heart Journal, 2014, 168, 682-689.e1.	2.7	365
63	Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists. Circulation, 2001, 103, 201-206.	1.6	359
64	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet, The, 2016, 388, 2142-2152.	13.7	357
65	Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery, 2003, 2, 15-28.	46.4	346
66	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	6.1	346
67	Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention. Circulation, 2001, 103, 961-966.	1.6	336
68	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of the American College of Cardiology, 2021, 78, e187-e285.	2.8	336
69	Adaptive Designs for Clinical Trials. New England Journal of Medicine, 2016, 375, 65-74.	27.0	335
70	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. Archives of Internal Medicine, 2010, 170, 1892.	3.8	319
71	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	2.8	319
72	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 144, e368-e454.	1.6	319

#	ARTICLE	IF	CITATIONS
73	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology, 2002, 39, 9-14.	2.8	313
74	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. Journal of the American College of Cardiology, 2000, 35, 922-928.	2.8	312
75	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. American Journal of Cardiology, 2005, 95, 1218-1222.	1.6	304
76	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	2.8	303
77	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, 157, 682-691.e2.	1.3	299
78	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 2306-2315.	2.8	296
79	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
80	CPAP versus Oxygen in Obstructive Sleep Apnea. New England Journal of Medicine, 2014, 370, 2276-2285.	27.0	294
81	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	2.2	293
82	International Expert Consensus on Switching Platelet P2Y <sub>12</sub> Receptor-Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
83	Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal, 2008, 30, 192-201.	2.2	290
84	Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal, 2006, 27, 647-654.	2.2	286
85	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	13.7	286
86	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation, 2010, 122, 2619-2633.	1.6	281
87	Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. European Heart Journal, 2009, 30, 2318-2326.	2.2	277
88	Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA - Journal of the American Medical Association, 2020, 324, 703.	7.4	269
89	Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery. Circulation, 2001, 103, 363-368.	1.6	266
90	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 280-288.	2.8	259

#	ARTICLE	IF	CITATIONS
91	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. <i>European Heart Journal</i> , 2020, 41, 3925-3932.	2.2	257
92	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	27.0	255
93	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 204.	6.1	249
94	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines® Stroke Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 543-549.	2.2	247
95	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. <i>American Heart Journal</i> , 2008, 156, 855-863.e2.	2.7	243
96	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 992-997.	1.6	241
97	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241
98	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1135-1147.	2.4	240
99	Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 1549.	7.4	238
100	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. <i>European Heart Journal</i> , 2014, 35, 2864-2872.	2.2	238
101	Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention. <i>Circulation</i> , 2002, 105, 691-696.	1.6	237
102	The REDuction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. <i>American Heart Journal</i> , 2006, 151, 786.e1-786.e10.	2.7	235
103	Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2411.	7.4	232
104	Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 610-620.	27.0	229
105	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 356-366.	11.4	224
106	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
107	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet</i> , 2010, 376, 517-523.	13.7	222
108	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 682-689.	3.1	221



#	ARTICLE	IF	CITATIONS
109	Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Atherosclerosis</i> , 2009, 204, e86-e92.	0.8	220
110	Diagnosis and Treatment of Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 662.	7.4	219
111	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	2.8	218
112	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
113	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	2.8	208
114	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
115	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017, 40, 69-76.	8.6	205
116	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2051-2066.	2.8	203
117	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	6.1	198
118	Temporal Trends and Sex Differences in Revascularization and Outcomes of ST-Segment Elevation Myocardial Infarction in Younger Adults in the United States. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1961-1972.	2.8	196
119	Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions. <i>Circulation</i> , 2003, 107, 1750-1756.	1.6	195
120	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2004, 148, 263-268.	2.7	193
121	Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2017, 136, 2325-2336.	1.6	193
122	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
123	Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. <i>Stroke</i> , 2004, 35, 528-532.	2.0	190
124	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	3.4	188
125	Non-adherence to cardiovascular medications. <i>European Heart Journal</i> , 2014, 35, 3267-3276.	2.2	188
126	Targeting cardiovascular inflammation: next steps in clinical translation. <i>European Heart Journal</i> , 2021, 42, 113-131.	2.2	186



#	ARTICLE	IF	CITATIONS
127	An International Model to Predict Recurrent Cardiovascular Disease. American Journal of Medicine, 2012, 125, 695-703.e1.	1.5	184
128	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
129	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUSâ€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	2.8	179
130	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	7.4	179
131	Left Ventricular Thrombus After Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 642.	6.1	171
132	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including) Tj ETQq0 0 0 rgBT /Overlock 10 T College of Cardiology, 2013, 61, 872-879.	2.8	170
133	Long-Term Cardiovascular Risk inÂWomenÂWith Hypertension DuringÂPregnancy. Journal of the American College of Cardiology, 2019, 74, 2743-2754.	2.8	169
134	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. European Heart Journal, 2013, 34, 1204-1214.	2.2	167
135	Intensifying Platelet Inhibition â€” Navigating between Scylla and Charybdis. New England Journal of Medicine, 2007, 357, 2078-2081.	27.0	164
136	Why are acute ischemic stroke patients not receiving IV tPA?. Neurology, 2016, 87, 1565-1574.	1.1	159
137	Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European Heart Journal, 2009, 30, 1195-1202.	2.2	157
138	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
139	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
140	Rationale and design of <scp>REDUCEâ€“IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€“Intervention Trial. Clinical Cardiology, 2017, 40, 138-148.	1.8	154
141	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
142	The Influence of Peripheral Arterial Disease on Outcomes. Journal of the American College of Cardiology, 2006, 48, 1567-1572.	2.8	152
143	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Annals of Internal Medicine, 2009, 150, 379.	3.9	152
144	Unmet Need for AdjunctiveÂDyslipidemiaÂTherapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology, 2018, 72, 330-343.	2.8	152

#	ARTICLE	IF	CITATIONS
145	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 2048-2090.	2.8	146
146	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. Journal of the American College of Cardiology, 2018, 71, 292-302.	2.8	145
147	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	7.4	144
148	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	8.6	141
149	The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet, The, 2019, 393, 2155-2167.	13.7	140
150	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y <sub>12</sub> inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	2.2	138
151	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11,473 patients. European Heart Journal, 2017, 38, ehw627.	2.2	138
152	Need to Test the Arterial Inflammation Hypothesis. Circulation, 2002, 106, 136-140.	1.6	137
153	Ross Procedure in Adults for Cardiologists and Cardiac Surgeons. Journal of the American College of Cardiology, 2018, 72, 2761-2777.	2.8	135
154	Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. American Heart Journal, 2000, 140, 67-73.	2.7	133
155	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	1.7	133
156	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	2.2	133
157	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 543-549.	2.2	132
158	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Journal of Thrombosis and Thrombolysis, 2012, 34, 44-55.	2.1	131
159	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
160	Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. Journal of the American College of Cardiology, 2015, 65, 2079-2088.	2.8	130
161	Metabolic Surgery. Journal of the American College of Cardiology, 2018, 71, 670-687.	2.8	130
162	Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes. Circulation, 2005, 112, 906-922.	1.6	129

#	ARTICLE	IF	CITATIONS
163	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1000-1009.	1.5	128
164	Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	128
165	Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. The Lancet Digital Health, 2020, 2, e486-e488.	12.3	128
166	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	127
167	Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 315-324.	2.9	127
168	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	2.8	126
169	Cardiovascular Toxicities of ImmuneÂCheckpointÂInhibitors. Journal of the American College of Cardiology, 2019, 74, 1714-1727.	2.8	124
170	Percutaneous Coronary Intervention inÂNative Coronary Arteries Versus BypassÂGrafts in Patients With Prior Coronary Artery Bypass Graft Surgery. JACC: Cardiovascular Interventions, 2016, 9, 884-893.	2.9	122
171	Enteric Coating and AspirinÂNonresponsiveness in PatientsÂWith TypeÂ2ÂDiabetes Mellitus. Journal of the American College of Cardiology, 2017, 69, 603-612.	2.8	121
172	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100997.	7.1	121
173	A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. Journal of the American College of Cardiology, 2012, 59, 1304-1311.	2.8	120
174	Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis. Journal of the American College of Cardiology, 2016, 67, 392-403.	2.8	120
175	Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations. Archives of Internal Medicine, 2004, 164, 2106.	3.8	119
176	Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European Heart Journal, 2010, 31, 1257-1265.	2.2	119
177	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
178	Regional Variation in the Incidence and Outcomes of In-Hospital Cardiac Arrest in the United States. Circulation, 2015, 131, 1415-1425.	1.6	118
179	Cocaine and Marijuana Use Among YoungÂAdults With Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 2540-2551.	2.8	118
180	Stroke Outcomes in the COMPASS Trial. Circulation, 2019, 139, 1134-1145.	1.6	118

#	ARTICLE	IF	CITATIONS
181	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	2.7	117
182	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	2.2	117
183	A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. European Heart Journal, 2007, 28, 664-672.	2.2	115
184	Culprit-only or multivessel revascularization in patients with acute coronary syndromes. American Heart Journal, 2008, 155, 140-146.	2.7	115
185	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelinesâ€“Heart Failure registry. American Heart Journal, 2016, 182, 9-20.	2.7	115
186	Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis. Archives of Internal Medicine, 2012, 172, 1086.	3.8	109
187	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents. Circulation, 2020, 142, 1425-1436.	1.6	109
188	Platelet Inhibition With Ticagrelor 60ÂmgÂVersus 90 mg Twice Daily in theÂPEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	2.8	108
189	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	1.3	108
190	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
191	Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry. Mayo Clinic Proceedings, 2020, 95, 1613-1620.	3.0	107
192	Synthesizing Lessons Learned From Get With The Guidelines. Circulation, 2013, 128, 2447-2460.	1.6	106
193	Increase in Endovascular Therapy in Get With The Guidelines-Stroke After the Publication of Pivotal Trials. Circulation, 2017, 136, 2303-2310.	1.6	106
194	Association of Chronic Kidney Disease With In-Hospital Outcomes of Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 2050-2060.	2.9	106
195	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	13.7	105
196	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. European Heart Journal, 2016, 38, ehw325.	2.2	104
197	Association of Cardiovascular Disease With Respiratory Disease. Journal of the American College of Cardiology, 2019, 73, 2166-2177.	2.8	104
198	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104

#	ARTICLE	IF	CITATIONS
199	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
200	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	3.9	103
201	Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2017, 38, 3082-3089.	2.2	103
202	Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 707-717.	2.8	103
203	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3370-3372.	2.8	102
204	Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 708-715.	2.2	100
205	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus—Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. <i>American Heart Journal</i> , 2011, 162, 818-825.e6.	2.7	98
206	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	6.1	97
207	DECLARE-TIMI 58: Participants' baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	4.4	96
208	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 618-620.	1.6	96
209	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , 2019, 380, 1825-1833.	27.0	96
210	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
211	ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2230-2245.	2.8	95
212	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.8	95
213	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 317-325.	1.8	94
214	The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. <i>European Heart Journal</i> , 2017, 38, 3488-3492.	2.2	94
215	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
216	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1852.	7.4	94

#	ARTICLE	IF	CITATIONS
217	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 619-629.	2.8	92
218	Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. New England Journal of Medicine, 2019, 380, 132-141.	27.0	92
219	Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2020, 323, 2170.	7.4	92
220	Percutaneous Coronary Intervention in 2018. JAMA - Journal of the American Medical Association, 2018, 319, 2127.	7.4	91
221	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90
222	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. American Heart Journal, 2012, 163, 182-190.e4.	2.7	89
223	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	2.7	89
224	Aspirin for Primary Prevention of Cardiovascular Events. Journal of the American College of Cardiology, 2019, 73, 2915-2929.	2.8	89
225	Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, 62, 286-290.	2.8	88
226	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	6.1	88
227	Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study. Diabetes Care, 2018, 41, 171-177.	8.6	88
228	Quality of Care and Outcomes for In-Hospital Ischemic Stroke. Stroke, 2014, 45, 231-238.	2.0	87
229	Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2018, 7, e008657.	3.7	87
230	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	13.7	87
231	Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. Journal of the American College of Cardiology, 2003, 41, 20-25.	2.8	86
232	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	2.2	86
233	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	6.1	86
234	Association of Severe Obstructive Sleep Apnea and Elevated Blood Pressure Despite Antihypertensive Medication Use. Journal of Clinical Sleep Medicine, 2014, 10, 835-843.	2.6	84



#	ARTICLE	IF	CITATIONS
235	β <sub>2</sub> -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 872-881.	2.2	84
236	Biomechanical Modeling to Improve Coronary Artery Bifurcation Stenting. JACC: Cardiovascular Interventions, 2015, 8, 1281-1296.	2.9	84
237	Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. Journal of Thrombosis and Thrombolysis, 2018, 46, 440-450.	2.1	84
238	Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. JAMA - Journal of the American Medical Association, 2009, 302, 2207.	7.4	83
239	Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial. American Journal of Gastroenterology, 2011, 106, 272-277.	0.4	83
240	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	83
241	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 2019, 140, 2054-2062.	1.6	83
242	Cardiac involvement in the long-term implications of COVID-19. Nature Reviews Cardiology, 2022, 19, 332-341.	13.7	83
243	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
244	Prasugrel in Clinical Practice. New England Journal of Medicine, 2009, 361, 940-942.	27.0	81
245	Variations in Coronary Artery Disease Secondary Prevention Prescriptions Among Outpatient Cardiology Practices. Journal of the American College of Cardiology, 2014, 63, 539-546.	2.8	81
246	Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke. Stroke, 2014, 45, 1387-1395.	2.0	81
247	Race/Ethnic Differences in the Risk of Hemorrhagic Complications Among Patients With Ischemic Stroke Receiving Thrombolytic Therapy. Stroke, 2014, 45, 2263-2269.	2.0	81
248	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation, 2015, 132, 1347-1353.	1.6	81
249	Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. Stroke, 2017, 48, 946-954.	2.0	81
250	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 140, 529-537.	1.6	81
251	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
252	Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting. Stroke, 2001, 32, 2328-2332.	2.0	79



#	ARTICLE	IF	CITATIONS
253	Aspirin and Clopidogrel in Acute Coronary Syndromes. Archives of Internal Medicine, 2003, 163, 1145.	3.8	79
254	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	4.5	79
255	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Journal of the American College of Cardiology, 2019, 74, 1159-1161.	2.8	79
256	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	6.1	77
257	Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry. European Heart Journal, 2020, 41, 4127-4137.	2.2	77
258	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	6.1	76
259	Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. Lancet, The, 2020, 396, 669-683.	13.7	76
260	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021, 144, 1295-1307.	1.6	75
261	Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation, 2021, 144, 728-745.	1.6	75
262	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. Circulation, 2013, 127, 730-738.	1.6	74
263	Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2015, 8, e002258.	3.9	74
264	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	2.8	74
265	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	8.6	73
266	Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. American Journal of Medicine, 2020, 133, 605-612.e1.	1.5	73
267	Linear and Nonlinear Mendelian Randomization Analyses of the Association Between Diastolic Blood Pressure and Cardiovascular Events. Circulation, 2021, 143, 895-906.	1.6	73
268	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. American Heart Journal, 2012, 163, 768-776.e2.	2.7	72
269	Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry. Clinical Cardiology, 2013, 36, 721-727.	1.8	72
270	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39, 750-757a.	2.2	72

#	ARTICLE	IF	CITATIONS
271	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	8.6	72
272	Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery. <i>JAMA Internal Medicine</i> , 2020, 180, 1638.	5.1	72
273	Association of Preoperatively Diagnosed Patent Foramen Ovale With Perioperative Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 452.	7.4	71
274	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	6.1	71
275	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	13.7	71
276	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016, 37, ehv482.	2.2	70
277	Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. <i>Lancet, The</i> , 2018, 391, 1997-2007.	13.7	70
278	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
279	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	9.0	70
280	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. <i>Circulation</i> , 2000, 102, 28-34.	1.6	69
281	Racial/Ethnic and Sex Differences in Emergency Medical Services Transport Among Hospitalized US Stroke Patients: Analysis of the National Get With The Guidelines-Stroke Registry. <i>Journal of the American Heart Association</i> , 2015, 4, e002099.	3.7	69
282	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	2.8	69
283	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , 2019, 30, 609-613.	16.2	69
284	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	2.8	69
285	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1633-1642.	2.8	69
286	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	2.8	69
287	The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 50-56.	2.1	69
288	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. <i>Circulation</i> , 2009, 120, 560-567.	1.6	68

#	ARTICLE	IF	CITATIONS
289	Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2017, 2, 732.	6.1	68
290	Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2878-2894.	2.8	68
291	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. <i>European Heart Journal Supplements</i> , 2020, 22, J34-J48.	0.1	68
292	Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. <i>Thrombosis and Haemostasis</i> , 2010, 104, 657-663.	3.4	67
293	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100933.	7.1	67
294	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5476.	2.3	66
295	Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 541-549.	2.2	65
296	Carotid Atherosclerosis and Risk of Subsequent Coronary Event in Outpatients With Atherothrombosis. <i>Stroke</i> , 2013, 44, 373-379.	2.0	65
297	Design and Rationale of the DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	1.8	65
298	Sex and Racial Disparities in Cardiac Rehabilitation Referral at Hospital Discharge and Gaps in Long-Term Mortality. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	65
299	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	7.4	65
300	Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke. <i>Stroke</i> , 2005, 36, 2289-2292.	2.0	64
301	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	1.7	64
302	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	2.2	64
303	Effect of Influenza on Outcomes in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 112-117.	4.1	64
304	Comparison of Acute Ischemic Stroke Care and Outcomes Between Comprehensive Stroke Centers and Primary Stroke Centers in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004512.	2.2	63
305	Association between COVID-19 outcomes and mask mandates, adherence, and attitudes. <i>PLoS ONE</i> , 2021, 16, e0252315.	2.5	63
306	Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	62

#	ARTICLE	IF	CITATIONS
307	Ross Procedure vs Mechanical Aortic Valve Replacement in Adults. JAMA Cardiology, 2018, 3, 978.	6.1	62
308	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal, 2019, 40, 1553-1562.	2.2	62
309	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial" Circulation, 2015, 132, e121-2.	1.6	61
310	Periodontal Inflammation and the Risk of Cardiovascular Disease. Current Atherosclerosis Reports, 2020, 22, 28.	4.8	61
311	Association of Influenza Vaccination With Cardiovascular Risk. JAMA Network Open, 2022, 5, e228873.	5.9	61
312	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). American Journal of Cardiology, 2010, 105, 667-671.	1.6	60
313	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. Journal of the American College of Cardiology, 2017, 70, 2171-2185.	2.8	59
314	Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines"Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 189, 85-93.	2.7	58
315	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	2.8	58
316	Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S36-44.	2.2	57
317	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open, 2017, 5, E152-E177.	2.4	57
318	Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography. Journal of the American College of Cardiology, 2020, 75, 1311-1320.	2.8	57
319	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of Cardiovascular Computed Tomography, 2022, 16, 54-122.	1.3	57
320	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) Tj ETQq0 0 0 ngBT /Overlock 10 Tf 5	1.8	56
321	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	2.8	56
322	Incidence, Characteristics, Predictors, and Outcomes of Surgical Explantation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 76, 1848-1859.	2.8	56
323	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	2.9	56
324	Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension. Annals of Internal Medicine, 2020, 173, 685-693.	3.9	55

#	ARTICLE	IF	CITATIONS
325	Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the American College of Cardiology, 2004, 43, 972-978.	2.8	54
326	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. BMJ, The, 2015, 351, h3786.	6.0	54
327	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 2142-2150.	8.6	54
328	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. Journal of the American Heart Association, 2018, 7, e009217.	3.7	54
329	A low-cost machine learning-based cardiovascular/stroke risk assessment system: integration of conventional factors with image phenotypes. Cardiovascular Diagnosis and Therapy, 2019, 9, 420-430.	1.7	54
330	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal, 2020, 41, 2304-2312.	2.2	54
331	Mechanical Thrombectomy for Acute Ischemic Stroke. Journal of the American College of Cardiology, 2015, 66, 2498-2505.	2.8	53
332	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	53
333	Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. American Journal of Cardiology, 2018, 122, 1959-1964.	1.6	53
334	The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. European Heart Journal, 2021, 42, 1728-1738.	2.2	53
335	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 383-392.	2.2	52
336	Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke, 2017, 48, 1810-1817.	2.0	52
337	Use of Cardiac Computerized Tomography to Predict Neo Left Ventricular Outflow Tract Obstruction Before Transcatheter Mitral Valve Replacement. Journal of the American Heart Association, 2017, 6, .	3.7	52
338	Safety and Efficacy of Double Antithrombotic Therapy With Non Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2020, 9, e017212.	3.7	52
339	Potent P2Y <sub>12</sub> Inhibitors in Men Versus Women. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
340	Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. European Heart Journal, 2017, 38, 2827-2835.	2.2	51
341	Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Tj ETQq1 1 0.784314 rgBT /Overl	1.6	51
342	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal, 2020, 41, 2248-2258.	2.2	51

#	ARTICLE	IF	CITATIONS
343	Regression to the Mean in SYMPPLICITYÂHTN-3. Journal of the American College of Cardiology, 2016, 68, 2016-2025.	2.8	50
344	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelinesâ€Heart Failure Registry. JAMA Cardiology, 2018, 3, 917.	6.1	50
345	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	2.8	50
346	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	3.9	49
347	Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	49
348	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10Â854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 2018, 39, 4112-4121.	2.2	49
349	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
350	Cardiovascular Mortality After TypeÂ1ÂandÂType 2 Myocardial Infarction inÂYoung Adults. Journal of the American College of Cardiology, 2020, 75, 1003-1013.	2.8	49
351	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	8.6	49
352	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis. JACC: CardioOncology, 2021, 3, 619-634.	4.0	49
353	Association of Chronic Renal Insufficiency With InÂHospital Outcomes After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2015, 4, e002069.	3.7	48
354	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take NonÂVitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation, 2017, 135, 1024-1035.	1.6	48
355	Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. Biomedicine and Pharmacotherapy, 2018, 98, 149-156.	5.6	48
356	Addressing bias: artificial intelligence in cardiovascular medicine. The Lancet Digital Health, 2020, 2, e635-e636.	12.3	48
357	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 75, 2297-2308.	2.8	48
358	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	2.7	48
359	Clinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2012, 43, 2376-2381.	2.0	47
360	Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel. Journal of the American College of Cardiology, 2014, 63, 769-777.	2.8	47



#	ARTICLE	IF	CITATIONS
361	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47
362	Contemporary Sex-Based Differences by Age in Presenting Characteristics, Use of an Early Invasive Strategy, and In-hospital Mortality in Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States. Circulation: Cardiovascular Interventions, 2018, 11, e005735.	3.9	47
363	Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes. Atherosclerosis, 2012, 221, 527-535.	0.8	46
364	Antiplatelet Therapy and Proton Pump Inhibition. Circulation, 2012, 125, 375-380.	1.6	46
365	Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelines Stroke. Journal of the American Heart Association, 2016, 5, .	3.7	46
366	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
367	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46
368	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCC-DRT-Registry. Circulation: Cardiovascular Interventions, 2021, 14, e010195.	3.9	46
369	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or <scp>TIA</scp>: Insights From the <scp>REACH</scp> Registry. Clinical Cardiology, 2016, 39, 670-677.	1.8	45
370	New-Generation Coronary Stents: Current Data and Future Directions. Current Atherosclerosis Reports, 2017, 19, 14.	4.8	45
371	Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States. JAMA Cardiology, 2017, 2, 25.	6.1	45
372	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. European Heart Journal, 2018, 39, 2255-2262.	2.2	45
373	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
374	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovascular Research, 2021, 117, 1070-1077.	3.8	45
375	Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. European Heart Journal, 2021, 42, 1019-1034.	2.2	45
376	Anti-Inflammatory Agents and Antioxidants as a Possible "Third Great Wave" in Cardiovascular Secondary Prevention. American Journal of Cardiology, 2008, 101, S4-S13.	1.6	44
377	Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	44
378	Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States. JAMA Cardiology, 2017, 2, 1322.	6.1	44



#	ARTICLE	IF	CITATIONS
379	Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 430.	9.0	44
380	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
381	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. <i>American Journal of Medicine</i> , 2014, 127, 53-60.e1.	1.5	43
382	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. <i>Circulation</i> , 2015, 132, 1404-1413.	1.6	43
383	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clinical Cardiology</i> , 2017, 40, 932-939.	1.8	43
384	Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. <i>Clinical Cardiology</i> , 2018, 41, 758-768.	1.8	43
385	Antithrombotic Therapy for Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2450-2467.	2.8	43
386	The Consequences of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2020, 76, 342-345.	2.8	43
387	Using C-reactive protein to assess cardiovascular disease risk.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 634-640.	1.3	43
388	Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1760-1765.	2.8	42
389	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2345-2350.	1.6	42
390	Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure. <i>Hypertension</i> , 2015, 66, 1130-1137.	2.7	42
391	Leaflet Thrombosis in Surgically Explanted or Post-Mortem TAVR Valves. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 82-85.	5.3	42
392	How I use laboratory monitoring of antiplatelet therapy. <i>Blood</i> , 2017, 130, 713-721.	1.4	42
393	Meta-Analysis and Trial Sequential Analysis Comparing Percutaneous Ventricular Assist Devices Versus Intra-Aortic Balloon Pump During High-Risk Percutaneous Coronary Intervention or Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2018, 122, 1330-1338.	1.6	42
394	Association of the New Peer Group "Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e192987.	5.9	42
395	Characteristics of Randomized Clinical Trials in Surgery From 2008 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2114494.	5.9	42
396	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42

#	ARTICLE	IF	CITATIONS
397	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 483-493.	4.1	41
398	Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization. Stroke, 2017, 48, 412-419.	2.0	41
399	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension, 2018, 71, 168-176.	2.7	41
400	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	2.8	41
401	Tailoring Antiplatelet Therapy Based on Pharmacogenomics. JAMA - Journal of the American Medical Association, 2009, 302, 896.	7.4	40
402	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40
403	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Circulation, 2016, 134, 861-871.	1.6	40
404	Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction. JAMA Cardiology, 2019, 4, 120.	6.1	40
405	Twitter-based learning for continuing medical education?. European Heart Journal, 2020, 41, 4376-4379.	2.2	40
406	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal, 2022, 43, 1715-1727.	2.2	40
407	Oral Glycoprotein IIb/IIIa Inhibitors. American Journal of Cardiovascular Drugs, 2001, 1, 421-428.	2.2	39
408	Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. American Journal of Cardiology, 2003, 92, 136-140.	1.6	39
409	Advancing the Care of Cardiac Patients Using Registry Data. JAMA - Journal of the American Medical Association, 2010, 303, 2188.	7.4	39
410	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart, 2014, 1, e000068.	2.3	39
411	Study of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry. Clinical Cardiology, 2017, 40, 955-961.	1.8	39
412	Comparison of Outcomes in Elective Endovascular Aortic Repair vs Open Surgical Repair of Abdominal Aortic Aneurysms. JAMA Network Open, 2019, 2, e196578.	5.9	39
413	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942.	2.8	39
414	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabolism, 2019, 30, 847-849.	16.2	39

#	ARTICLE	IF	CITATIONS
415	Metabolic Surgery for Hypertension in Patients With Obesity. <i>Circulation Research</i> , 2019, 124, 1009-1024.	4.5	39
416	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
417	Global perspective on carotid intima-media thickness and plaque: should the current measurement guidelines be revisited?. <i>International Angiology</i> , 2020, 38, 451-465.	0.9	39
418	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
419	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2060-2072.	2.8	39
420	Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. <i>Nature Reviews Cardiology</i> , 2010, 7, 461-467.	13.7	38
421	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38
422	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	2.7	38
423	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	2.8	38
424	Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. <i>Cardiovascular Research</i> , 2020, 116, 479-482.	3.8	38
425	Infective Endocarditis After Surgical and Transcatheter Aortic Valve Replacement: A State of the Art Review. <i>Journal of the American Heart Association</i> , 2020, 9, e017347.	3.7	38
426	Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry. <i>JAMA Network Open</i> , 2020, 3, e209649.	5.9	38
427	Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES.) <i>Tj ETQq1 1 0,784314 reBT /Over</i>	1.6	38
428	Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. <i>Stroke</i> , 2014, 45, 2745-2749.	2.0	37
429	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	1.7	37
430	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2018, 131, 575-577.	1.5	37
431	Bariatric surgery is associated with a lower rate of death after myocardial infarction and stroke: A nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2058-2067.	4.4	37
432	The COVID-19 pandemic: a catalyst to improve clinical trials. <i>Nature Reviews Cardiology</i> , 2020, 17, 673-675.	13.7	37

#	ARTICLE	IF	CITATIONS
433	Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era. JAMA Neurology, 2020, 77, 1486.	9.0	37
434	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut, 2022, 71, 254-264.	12.1	37
435	Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes. Circulation, 2001, 104, 2772-2777.	1.6	36
436	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. Journal of the American Society of Hypertension, 2015, 9, 769-779.	2.3	36
437	Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressureâ€“Lowering Effect of Renal Denervation. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 14-22.	2.2	36
438	Relation of Obesity to Survival After In-Hospital Cardiac Arrest. American Journal of Cardiology, 2016, 118, 662-667.	1.6	36
439	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. JAMA Cardiology, 2017, 2, 127.	6.1	36
440	Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. Journal of the American College of Cardiology, 2019, 73, 3281-3291.	2.8	36
441	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 140, 1451-1459.	1.6	36
442	Prevalence and Outcomes of Acute Ischemic Stroke Among Patients â‰¥50 Years of Age With Laboratory Confirmed COVID-19 Infection. American Journal of Cardiology, 2020, 130, 169-170.	1.6	36
443	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. JAMA Cardiology, 2021, 6, 880.	6.1	36
444	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation, 2021, 144, 1750-1759.	1.6	36
445	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	2.8	36
446	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. Stroke, 2014, 45, 3243-3250.	2.0	35
447	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 929-935.	2.2	35
448	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. JACC: Cardiovascular Interventions, 2015, 8, 424-433.	2.9	35
449	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. Journal of the American College of Cardiology, 2016, 67, 936-947.	2.8	35
450	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€“glucose cotransporter 2 inhibitor therapy in <sc>DECLAREâ€“TIMI</sc> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	7.1	35

#	ARTICLE	IF	CITATIONS
451	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
452	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	2.2	35
453	Renal Artery Revascularization. JAMA Internal Medicine, 2014, 174, 1849.	5.1	34
454	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	3.9	34
455	Trends in Palliative Care Use in Veterans With Severe Heart Failure Using a Large National Cohort. JAMA Cardiology, 2016, 1, 617.	6.1	34
456	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	1.5	34
457	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart, 2017, 103, 1168-1176.	2.9	34
458	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 1861-1871.	2.8	34
459	CABG the clear choice for patients with diabetes and multivessel disease. Lancet, The, 2018, 391, 913-914.	13.7	34
460	Trends in utilization of mechanical circulatory support in patients hospitalized after out-of-hospital cardiac arrest. Resuscitation, 2018, 127, 105-113.	3.0	34
461	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
462	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 1362-1364.	2.8	34
463	Components and Trends in Door to Treatment Times for Endovascular Therapy in Get With The Guidelines-Stroke Hospitals. Circulation, 2019, 139, 169-179.	1.6	34
464	Ultrasound-based internal carotid artery plaque characterization using deep learning paradigm on a supercomputer: a cardiovascular disease/stroke risk assessment system. International Journal of Cardiovascular Imaging, 2021, 37, 1511-1528.	1.5	34
465	Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 829-839.	1.0	34
466	Virtual and Augmented Reality in Cardiovascular Care. JACC: Cardiovascular Imaging, 2022, 15, 519-532.	5.3	34
467	Hospital Variation in Home-Time After Acute Ischemic Stroke. Stroke, 2016, 47, 2627-2633.	2.0	33
468	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the <sc>REACH</sc> Registry. Clinical Cardiology, 2017, 40, 710-718.	1.8	33

#	ARTICLE	IF	CITATIONS
469	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. <i>European Heart Journal</i> , 2017, 38, 3211-3218.	2.2	33
470	Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database. <i>Structural Heart</i> , 2017, 1, 256-264.	0.6	33
471	Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1571-1582.	2.9	33
472	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	1.8	33
473	Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. <i>American Journal of Cardiology</i> , 2021, 156, 129-131.	1.6	33
474	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	2.7	33
475	Race and Ethnicity Considerations in Patients With Coronary Artery Disease and Stroke. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2483-2492.	2.8	33
476	Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. <i>American Heart Journal</i> , 2006, 151, 976.e7-976.e11.	2.7	32
477	EXAMINATION of new drug-eluting stentsâ€”top of the class!. <i>Lancet, The</i> , 2012, 380, 1453-1455.	13.7	32
478	Patient and Hospital Characteristics Associated With Inappropriate Percutaneous Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2274-2281.	2.8	32
479	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 345-352.	4.1	32
480	Troponin and the J-Curve of Diastolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1723-1726.	2.8	32
481	Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2018, 121, 32-40.	1.6	32
482	Comparison of Outcomes of Transfemoral Versus Transapical Approach for Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2018, 122, 1520-1526.	1.6	32
483	Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 233-247.	2.1	32
484	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
485	The association between coronary graft patency and clinical status in patients with coronary artery disease. <i>European Heart Journal</i> , 2021, 42, 1433-1441.	2.2	32
486	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	3.9	32



#	ARTICLE	IF	CITATIONS
487	Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 173, 102337.	2.2	32
488	Peroxisome proliferator-activated receptor $\beta$ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study. American Heart Journal, 2007, 154, 137-143.	2.7	31
489	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions. International Journal of Cardiology, 2014, 172, 29-35.	1.7	31
490	Insurance Status and Outcome after Intracerebral Hemorrhage: Findings from Get With The Guidelines-Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 283-292.	1.6	31
491	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	1.5	31
492	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. Circulation, 2016, 134, 723-733.	1.6	31
493	Contemporary Patterns of Early Coronary Angiography Use in Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2018, 11, 369-380.	2.9	31
494	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting. Circulation: Cardiovascular Interventions, 2018, 11, e006179.	3.9	31
495	Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals. JAMA Cardiology, 2018, 3, 1249.	6.1	31
496	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004729.	2.2	31
497	REDUCE-IT. European Heart Journal, 2019, 40, 1174-1175.	2.2	31
498	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation, 2019, 137, 205-212.	3.0	31
499	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	4.4	31
500	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. Journal of the American Heart Association, 2021, 10, e022125.	3.7	31
501	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	2.8	31
502	Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2017, 11, 624-637.	1.5	30
503	CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection—and Maybe More. Cell Metabolism, 2017, 26, 703-705.	16.2	30
504	Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. Journal of the American Heart Association, 2018, 7, e009745.	3.7	30



#	ARTICLE	IF	CITATIONS
505	Trends in Incidence, Characteristics, and In-Hospital Outcomes of Patients Presenting With Spontaneous Coronary Artery Dissection (From a National Population-Based Cohort Study Between) Tj ETQq1 1 0.784314 rgBT /Overlo	2.2	30
506	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004054.	2.2	30
507	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
508	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	4.0	30
509	Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2804-2815.	2.8	30
510	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	5.9	30
511	Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2431-2449.	2.8	30
512	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	13.7	30
513	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005, 150, 401.e1-401.e7.	2.7	29
514	Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. <i>Value in Health</i> , 2009, 12, 872-879.	0.3	29
515	Moving Toward Global Primordial Prevention in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1535-1537.	2.8	29
516	Clinical Effectiveness of Hydralazine and Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2016, 9, e002444.	3.9	29
517	Causes of Troponin Elevation and Associated Mortality in Young Patients. <i>American Journal of Medicine</i> , 2018, 131, 284-292.e1.	1.5	29
518	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021, 36, 2532-2535.	2.6	29
519	Low-cost preventive screening using carotid ultrasound in patients with diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2020, 25, 1132-1171.	3.0	29
520	Risk factors and outcomes for patients with vascular disease and serious bleeding events. <i>Heart</i> , 2011, 97, 1507-1512.	2.9	28
521	Trends in Management and Outcomes of ST-Elevation Myocardial Infarction in Patients With End-Stage Renal Disease in the United States. <i>American Journal of Cardiology</i> , 2015, 115, 1033-1041.	1.6	28
522	Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S73-80.	2.2	28

#	ARTICLE	IF	CITATIONS
523	Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2016, 133, 1512-1515.	1.6	28
524	Prevalence of Elective and Ruptured Abdominal Aortic Aneurysm Repairs by Age and Sex From 2003 to 2016 in Ontario, Canada. <i>JAMA Network Open</i> , 2018, 1, e185418.	5.9	28
525	Modes and timing of death in 66â€‰%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
526	Hospital distance, socioeconomic status, and timely treatment of ischemic stroke. <i>Neurology</i> , 2019, 93, e747-e757.	1.1	28
527	Restrictive versus liberal red blood cell transfusion for cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 179-185.	2.1	28
528	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	1.8	28
529	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. <i>Circulation</i> , 2020, 142, 1579-1590.	1.6	28
530	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
531	Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005977.	2.2	28
532	Randomized Trials in Cardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1593-1604.	2.8	28
533	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€‰lowering agents: Post hoc analyses from <sc>DECLAREâ€‰TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	4.4	28
534	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLAREâ€‰TIMI 58 trial. <i>European Heart Journal</i> , 2022, 43, 2958-2967.	2.2	28
535	Safety and Feasibility of Same-Day Discharge After Left Atrial Appendage Closure With the WATCHMAN Device. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009669.	3.9	28
536	EPA and DHA containing phospholipids have contrasting effects on membrane structure. <i>Journal of Lipid Research</i> , 2021, 62, 100106.	4.2	28
537	Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients â€‰%90 Years of Age. <i>Stroke</i> , 2016, 47, 2347-2354.	2.0	27
538	O PIONEERS!. <i>Circulation</i> , 2017, 135, 334-337.	1.6	27
539	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018, 131, 956-960.	1.5	27
540	Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?. <i>Circulation</i> , 2018, 137, 1429-1431.	1.6	27

#	ARTICLE	IF	CITATIONS
541	Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 343-348.	1.6	27
542	Toward Precision Policy – The Case of Cardiovascular Care. New England Journal of Medicine, 2018, 379, 2193-2195.	27.0	27
543	CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2019, 93, 1246-1252.	1.7	27
544	Coronary Embolism: A Systematic Review. Cardiovascular Revascularization Medicine, 2020, 21, 367-374.	0.8	27
545	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
546	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255.	6.1	27
547	Genetic Variation in Cardiometabolic Traits and Medication Targets and the Risk of Hypertensive Disorders of Pregnancy. Circulation, 2020, 142, 711-713.	1.6	27
548	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	8.6	27
549	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. Biomolecules, 2020, 10, 551.	4.0	27
550	Presence of Carotid and Peripheral Arterial Disease in Patients With Left Main Disease. American Journal of Cardiology, 2007, 100, 1087-1089.	1.6	26
551	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis, 2014, 111, 1141-1152.	3.4	26
552	Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage. American Heart Journal, 2014, 168, 398-404.	2.7	26
553	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. Journal of Thrombosis and Thrombolysis, 2015, 40, 317-322.	2.1	26
554	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. Circulation, 2016, 133, 248-255.	1.6	26
555	Heart failure event definitions in drug trials in patients with type 2 diabetes. Lancet Diabetes and Endocrinology, 2016, 4, 294-296.	11.4	26
556	Primary Prevention of Atherosclerosis. Journal of the American College of Cardiology, 2017, 70, 2992-2994.	2.8	26
557	Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 1778-1786.	2.8	26
558	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	1.5	26

#	ARTICLE	IF	CITATIONS
559	Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipidâ€”aspirin complex: results of a randomized, crossover, bioequivalence study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 554-562.	2.1	26
560	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. <i>Hypertension</i> , 2019, 73, 60-67.	2.7	26
561	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€”TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	4.4	26
562	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 801.	6.1	26
563	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€”PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	3.7	26
564	Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 104, 1171-1178.	1.6	25
565	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 58-65.	2.2	25
566	Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. <i>American Journal of Medicine</i> , 2014, 127, 728-738.	1.5	25
567	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>European Heart Journal</i> , 2014, 35, 1760-1768.	2.2	25
568	On the use of propensity scores in case of rare exposure. <i>BMC Medical Research Methodology</i> , 2016, 16, 38.	3.1	25
569	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	2.8	25
570	Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. <i>Circulation Journal</i> , 2017, 81, 1337-1345.	1.6	25
571	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005795.	3.9	25
572	Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Nonâ€”Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. <i>Stroke</i> , 2018, 49, 2237-2240.	2.0	25
573	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
574	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019, 42, e42-e44.	8.6	25
575	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	3.0	25
576	Effect of Acclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1693.	7.4	25

#	ARTICLE	IF	CITATIONS
577	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). American Journal of Cardiology, 2019, 123, 145-152.	1.6	25
578	Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis. Circulation, 2020, 142, 1342-1350.	1.6	25
579	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	8.6	25
580	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	2.8	25
581	Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease. American Journal of Cardiology, 2009, 103, 11A-19A.	1.6	24
582	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	24
583	Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis. American Heart Journal, 2017, 189, 59-67.	2.7	24
584	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017, 241, 87-96.	1.7	24
585	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis, 2018, 272, 80-86.	0.8	24
586	Public Reporting of Percutaneous Coronary Intervention Outcomes. JAMA Cardiology, 2018, 3, 635.	6.1	24
587	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology, 2019, 42, 498-505.	1.8	24
588	Reoperative Mitral Surgery Versus Transcatheter Mitral Valve Replacement: A Systematic Review. Journal of the American Heart Association, 2021, 10, e019854.	3.7	24
589	Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?. Circulation, 2021, 144, 4-6.	1.6	24
590	Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery. JAMA Network Open, 2021, 4, e2121867.	5.9	24
591	Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence. Reviews in Cardiovascular Medicine, 2020, 21, 541.	1.4	24
592	Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes. Journal of the American Heart Association, 2022, 11, e022010.	3.7	24
593	Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?. JACC: Heart Failure, 2014, 2, 583-585.	4.1	23
594	Routine invasive versus selective invasive strategies for Non-ST-elevation acute coronary syndromes: An Updated meta-analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2016, 88, 765-774.	1.7	23

#	ARTICLE	IF	CITATIONS
595	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	2.2	23
596	Association of Obesity With In-Hospital Mortality of Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 119, 1548-1554.	1.6	23
597	Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: A propensity score-matched analysis of in-hospital outcomes in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 771-779.	1.7	23
598	Diabetes Mellitus and Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2018, 131, 778-786.e1.	1.5	23
599	Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?. <i>Cell Metabolism</i> , 2018, 28, 813-815.	16.2	23
600	Temporal Trends and Outcomes of Percutaneous Coronary Interventions in Nonagenarians. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1872-1882.	2.9	23
601	Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2018, 269, 170-173.	1.7	23
602	Patent foramen ovale and long-term risk of ischaemic stroke after surgery. <i>European Heart Journal</i> , 2019, 40, 914-924.	2.2	23
603	Cardiovascular risk reduction with icosapent ethyl. <i>Current Opinion in Cardiology</i> , 2019, 34, 721-727.	1.8	23
604	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	3.0	23
605	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	3.0	23
606	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	3.8	23
607	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	2.3	23
608	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 774418.	2.4	23
609	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	2.2	23
610	Balancing the risks of stroke and bleeding in CKD. <i>Nature Reviews Nephrology</i> , 2015, 11, 200-202.	9.6	22
611	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 757-766.	2.2	22
612	Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 691-693.	4.4	22



#	ARTICLE	IF	CITATIONS
613	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 24-33.	2.8	22
614	Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 119, 1127-1134.	1.6	22
615	Assessment of Stable Coronary Lesions. <i>New England Journal of Medicine</i> , 2017, 376, 1879-1881.	27.0	22
616	Cangrelor Use in Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1712-1714.	2.9	22
617	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
618	A practical clinical approach to utilize cardiopulmonary exercise testing in the evaluation and management of coronary artery disease. <i>Current Opinion in Cardiology</i> , 2018, 33, 168-177.	1.8	22
619	Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2254-2261.	2.9	22
620	Association of Rankings With Cardiovascular Outcomes at Top-Ranked Hospitals vs Nonranked Hospitals in the United States. <i>JAMA Cardiology</i> , 2018, 3, 1222.	6.1	22
621	Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program. <i>JAMA Cardiology</i> , 2019, 4, 727.	6.1	22
622	Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 345-353.	1.7	22
623	Cholesterol-Years for ASCVD Risk Prediction and Treatment. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1517-1520.	2.8	22
624	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.7	22
625	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
626	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 91-112.	2.2	21
627	Right Heart Catheterization, Coronary Angiography, and Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e428-33.	1.6	21
628	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. <i>International Journal of Cardiology</i> , 2013, 163, 266-271.	1.7	21
629	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	3.4	21
630	Temperature and Precipitation Associate With Ischemic Stroke Outcomes in the United States. <i>Journal of the American Heart Association</i> , 2018, 7, e010020.	3.7	21



#	ARTICLE	IF	CITATIONS
631	Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1184-1187.	1.4	21
632	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal, 2018, 39, 3855-3863.	2.2	21
633	Stability After Initial Decline in Coronary Revascularization Rates in the United States. Annals of Thoracic Surgery, 2019, 108, 1404-1408.	1.3	21
634	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Medicine, 2019, 132, 733-739.	1.5	21
635	A Revolution in Omega-3 Fatty Acid Research. Journal of the American College of Cardiology, 2020, 76, 2098-2101.	2.8	21
636	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	5.1	21
637	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	2.7	21
638	Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open, 2021, 4, e2037438.	5.9	21
639	Intermediate-Term Outcomes of Endoscopic or Open Vein Harvesting for Coronary Artery Bypass Grafting. JAMA Network Open, 2021, 4, e211439.	5.9	21
640	Cangrelor Use Since FDA Approval. Journal of the American College of Cardiology, 2017, 69, 463-464.	2.8	20
641	Association between operator specialty and outcomes after carotid artery revascularization. Journal of Vascular Surgery, 2018, 67, 478-489.e6.	1.1	20
642	Myocardial Scar But Not Ischemia Is Associated With Defibrillator Shocks and Sudden Cardiac Death in Stable Patients With Reduced Left Ventricular Ejection Fraction. JACC: Clinical Electrophysiology, 2018, 4, 1200-1210.	3.2	20
643	Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007600.	4.8	20
644	Thrombolysis in young adults with stroke. Neurology, 2019, 92, e2784-e2792.	1.1	20
645	Running thin: implications of a heparin shortage. Lancet, The, 2020, 395, 534-536.	13.7	20
646	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	8.6	20
647	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Clinical Cardiology, 2012, 35, 722-729.	1.8	19
648	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. Circulation: Cardiovascular Interventions, 2014, 7, 813-820.	3.9	19

#	ARTICLE	IF	CITATIONS
649	When Is a Double Better Than a TRIPLE?. Journal of the American College of Cardiology, 2015, 65, 1630-1632.	2.8	19
650	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2016, 133, 2094-2098.	1.6	19
651	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	3.9	19
652	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 93-97.	1.0	19
653	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease. Circulation, 2017, 135, 819-821.	1.6	19
654	Meta-analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. American Journal of Cardiology, 2017, 119, 1949-1956.	1.6	19
655	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2017, 10, 1621-1630.	2.9	19
656	Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia. JACC Basic To Translational Science, 2018, 3, 327-329.	4.1	19
657	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine, 2019, 25, 640-655.	6.7	19
658	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	2.2	19
659	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 356-363.	3.0	19
660	Recurrent spontaneous coronary artery dissection in the United States. International Journal of Cardiology, 2020, 301, 34-37.	1.7	19
661	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 1690-1695.	4.4	19
662	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. European Journal of Heart Failure, 2021, 23, 384-392.	7.1	19
663	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	4.4	19
664	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
665	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	4.1	19
666	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2022, 10, 330-340.	11.4	19

#	ARTICLE	IF	CITATIONS
667	Ticagrelor in ACS—what does PLATO teach us?. <i>Nature Reviews Cardiology</i> , 2009, 6, 737-738.	13.7	18
668	Interaction between diabetes and a high ankle-brachial index on mortality risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 615-621.	1.8	18
669	Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. <i>JAMA Cardiology</i> , 2017, 2, 250.	6.1	18
670	Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. <i>The Cochrane Library</i> , 2017, 2017, CD011986.	2.8	18
671	Comparison of Outcomes of ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention During Off-Hours Versus On-Hours. <i>American Journal of Cardiology</i> , 2017, 120, 1742-1754.	1.6	18
672	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1648-1659.	1.8	18
673	Short- versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled analysis of six randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 178-189.	1.7	18
674	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 299-303.	2.1	18
675	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. <i>American Journal of Medicine</i> , 2019, 132, 840-846.	1.5	18
676	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	4.5	18
677	Getting to an Improved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020, 219, 70-77.	2.7	18
678	The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. <i>Current Diabetes Reports</i> , 2020, 20, 65.	4.2	18
679	Coronary Artery Calcium to Improve the Efficiency of Randomized Controlled Trials in Primary Cardiovascular Prevention. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1005-1016.	5.3	18
680	Patient-reported Outcomes After Metabolic Surgery Versus Medical Therapy for Diabetes. <i>Annals of Surgery</i> , 2021, 274, 524-532.	4.2	18
681	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	18
682	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1531-1540.	1.8	17
683	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. <i>American Heart Journal</i> , 2016, 173, 27-34.	2.7	17
684	Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	17

#	ARTICLE	IF	CITATIONS
685	Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States. <i>American Journal of Cardiology</i> , 2017, 120, 1869-1876.	1.6	17
686	Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. <i>Journal of Women's Health</i> , 2017, 26, 380-388.	3.3	17
687	Long-term Outcomes of Carotid Endarterectomy Versus Stenting in a Multicenter Population-based Canadian Study. <i>Annals of Surgery</i> , 2018, 268, 364-373.	4.2	17
688	Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. <i>European Journal of Heart Failure</i> , 2018, 20, 359-369.	7.1	17
689	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007045.	3.9	17
690	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	1.6	17
691	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
692	Transcatheter Aortic Valve Replacement in Low-Risk Patients. <i>Circulation</i> , 2019, 140, 801-803.	1.6	17
693	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry. <i>American Heart Journal</i> , 2019, 211, 1-10.	2.7	17
694	Relation of Concomitant Heart Failure to Outcomes in Patients Hospitalized With Influenza. <i>American Journal of Cardiology</i> , 2019, 123, 1478-1480.	1.6	17
695	Transcatheter versus surgical aortic valve replacement in low-risk surgical patients: A meta-analysis of randomized clinical trials. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 838-842.	0.8	17
696	Aortic Valve Replacement in Bioprosthetic Failure: Insights From The Society of Thoracic Surgeons National Database. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1637-1642.	1.3	17
697	Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1605-1606.	2.8	17
698	Effects of Epeleuton, a Novel Synthetic Second-Generation $\omega$ -3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. <i>Journal of the American Heart Association</i> , 2020, 9, e016334.	3.7	17
699	Increased Prevalence of Myocardial Injury in Patients with SARS-CoV-2 Viremia. <i>American Journal of Medicine</i> , 2021, 134, 542-546.	1.5	17
700	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	3.7	17
701	Intracranial Hemorrhage During Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1372-1384.	2.8	17
702	A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1426-1438.e2.	0.8	17

#	ARTICLE	IF	CITATIONS
703	The promise of renal denervation. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 498-500.	1.3	17
704	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 840-845.	2.7	16
705	Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics. <i>Stroke</i> , 2016, 47, 1278-1285.	2.0	16
706	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines® Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	16
707	More CREDENCE for SGLT2 Inhibition. <i>Circulation</i> , 2019, 140, 1448-1450.	1.6	16
708	Practical considerations for cangrelor use in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 39-44.	1.0	16
709	Palliative Care Use in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 113-117.	2.8	16
710	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-AHF in perspective. <i>ESC Heart Failure</i> , 2020, 7, 3261-3267.	3.1	16
711	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	4.4	16
712	Clinical features and prognosis of patients with spontaneous coronary artery dissection. <i>International Journal of Cardiology</i> , 2020, 312, 33-36.	1.7	16
713	Improving Terminology to Describe Coronary Artery Procedures. <i>Journal of the American College of Cardiology</i> , 2021, 78, 180-188.	2.8	16
714	Role of Cardiac CT in Pre-Procedure Planning for Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1571-1580.	5.3	16
715	Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. <i>Cell Reports Medicine</i> , 2020, 1, 100018.	6.5	16
716	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. <i>EuroIntervention</i> , 2018, 13, e1841-e1849.	3.2	16
717	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1550-1563.	2.8	16
718	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 561-567.	2.6	16
719	Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 19.	1.6	16
720	Endovascular Therapy for Stroke. <i>Circulation</i> , 2014, 129, 1152-1160.	1.6	15

#	ARTICLE	IF	CITATIONS
721	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S117-S124.	2.2	15
722	Cardiovascular health awareness and the effect of an educational intervention on school-aged children in a rural district of India. <i>Indian Heart Journal</i> , 2016, 68, 43-47.	0.5	15
723	Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call to action for optimal training of the next generation of interventionalists. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 1010-1015.	1.7	15
724	Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004397.	2.2	15
725	Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003359.	2.2	15
726	Cardiovascular Biomarkers After Metabolic Surgery Versus Medical Therapy for Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 261-263.	2.8	15
727	THEMIS and THEMIS-PCI. <i>European Heart Journal</i> , 2019, 40, 3378-3381.	2.2	15
728	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines "Heart Failure Program). <i>American Journal of Cardiology</i> , 2020, 125, 894-900.	1.6	15
729	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
730	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1647-1658.	2.0	15
731	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020, 5, 515.	6.1	15
732	Population-based long-term outcomes of open versus endovascular aortic repair of ruptured abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2020, 71, 1867-1878.e8.	1.1	15
733	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008349.	3.9	15
734	Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. <i>American Heart Journal</i> , 2021, 232, 105-115.	2.7	15
735	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 1226-1234.	6.3	15
736	Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. <i>International Angiology</i> , 2021, 40, 150-164.	0.9	15
737	The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. <i>Progress in Cardiovascular Diseases</i> , 2021, 69, 3-10.	3.1	15
738	Transcatheter aortic valve replacement same-day discharge for selected patients: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa556.	0.6	15



#	ARTICLE	IF	CITATIONS
739	COVID-19: An Unintended Force for Medical Revolution?. Journal of Invasive Cardiology, 2020, 32, E81-E82.	0.4	15
740	The National Cardiovascular Data Registry Data Quality Program 2020. Journal of the American College of Cardiology, 2022, 79, 1704-1712.	2.8	15
741	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
742	Successful "pre-closure" of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	14
743	Platelet Inhibition with Cangrelor during PCI. New England Journal of Medicine, 2013, 369, 393-394.	27.0	14
744	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. Journal of the American Heart Association, 2015, 4, e002061.	3.7	14
745	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 145-151.	4.8	14
746	Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2018, 91, 798-805.	1.7	14
747	Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction. Circulation, 2018, 138, 2855-2857.	1.6	14
748	Comparison of Causes and Associated Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical Aortic Valve Replacement in the United States (A National Readmission Database) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	14
749	Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation"Contradictory or Complementary?. JAMA Cardiology, 2019, 4, 311.	6.1	14
750	The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19. Journal of the American Heart Association, 2020, 9, e018274.	3.7	14
751	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	1.5	14
752	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	1.2	14
753	Using statins to treat inflammation in acute coronary syndromes: Are we there yet?. Cleveland Clinic Journal of Medicine, 2006, 73, 760-766.	1.3	14
754	Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. Journal of the American College of Cardiology, 2022, 79, 220-222.	2.8	14
755	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. Clinical Pharmacokinetics, 2022, 61, 465-479.	3.5	14
756	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009099.	3.9	14

#	ARTICLE	IF	CITATIONS
757	A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, 182, 102450.	2.2	14
758	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. European Heart Journal, 2022, 43, 2931-2945.	2.2	14
759	Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Current Cardiology Reports, 2001, 3, 63-71.	2.9	13
760	Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor. Mayo Clinic Proceedings, 2004, 79, 1107-1109.	3.0	13
761	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <sc>US</sc> Cardiologists. Clinical Cardiology, 2014, 37, 103-107.	1.8	13
762	Do We Really Know the CvLPRIT in Myocardial Infarction? Or Just Stent All Lesions?—. Journal of the American College of Cardiology, 2015, 65, 973-975.	2.8	13
763	Coronary CTA in the Evaluation of Stable Chest Pain. Journal of the American College of Cardiology, 2017, 69, 1771-1773.	2.8	13
764	Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2017, 318, 1439.	7.4	13
765	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005635.	3.9	13
766	Increased Free Testosterone Levels in Men with Uncontrolled Type 2 Diabetes Five Years After Randomization to Bariatric Surgery. Obesity Surgery, 2018, 28, 277-280.	2.1	13
767	Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2018, 13, 163-170.	0.9	13
768	Trends in Inpatient Complications After Transcatheter and Surgical Aortic Valve Replacement in the Transcatheter Aortic Valve Replacement Era. Circulation: Cardiovascular Interventions, 2018, 11, e007517.	3.9	13
769	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal, 2019, 212, 13-22.	2.7	13
770	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC: Cardiovascular Interventions, 2019, 12, 2346-2355.	2.9	13
771	Meta-analysis of optimal timing of coronary intervention in non-ST-elevation acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2020, 95, 185-193.	1.7	13
772	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Triple Therapy). JAMA Cardiology, 2020, 5, 1349.	1.6	13
773	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2020, 5, 1349.	6.1	13
774	Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes. American Journal of Cardiology, 2020, 130, 7-14.	1.6	13

#	ARTICLE	IF	CITATIONS
775	Meta-Analysis of Transradial vs Transfemoral Access for Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 141, 23-30.	1.6	13
776	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology, 2021, 77, 2366-2377.	2.8	13
777	Patient-specific computational simulation of coronary artery bifurcation stenting. Scientific Reports, 2021, 11, 16486.	3.3	13
778	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
779	Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction From National Cardiovascular Data Registry Chest Painâ€MI Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e008112.	2.2	13
780	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. , 2022, 1, .		13
781	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCEâ€T. Journal of the American Heart Association, 2022, 11, e024999.	3.7	13
782	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13
783	Association Between Periodontal Disease and Cardiovascular Disease (from the NHANES). American Journal of Cardiology, 2022, 178, 163-168.	1.6	13
784	Culprit-Only vs. Complete Revascularization During ST-Segment Elevation Myocardial Infarction. Progress in Cardiovascular Diseases, 2015, 58, 260-266.	3.1	12
785	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care, 2016, 39, 1329-1337.	8.6	12
786	Acute management of stroke patients taking nonâ€vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal, 2016, 182, 28-35.	2.7	12
787	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke, 2016, 47, 2066-2074.	2.0	12
788	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	1.6	12
789	Do We Need a Trial of DES Versus CABG Surgery in Diabetic Patients With ACS?. Journal of the American College of Cardiology, 2017, 70, 3007-3009.	2.8	12
790	Thoracic endovascular repair versus medical management for acute uncomplicated type <sc>B</sc> aortic dissection. Catheterization and Cardiovascular Interventions, 2018, 91, 1138-1143.	1.7	12
791	Birth and Maturation of Cardio-Oncology. JACC: CardioOncology, 2019, 1, 114-116.	4.0	12
792	Temporal Trends and Outcomes of Hospitalizations With Prinzmetal Angina: Perspectives From a National Database. American Journal of Medicine, 2019, 132, 1053-1061.e1.	1.5	12

#	ARTICLE	IF	CITATIONS
793	Association of peripheral artery disease with in-hospital outcomes after endovascular transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2019, 94, 249-255.	1.7	12
794	Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006031.	2.2	12
795	New Decade, New FDA Guidance for Diabetes Drug Development. Journal of the American College of Cardiology, 2020, 76, 2522-2526.	2.8	12
796	Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Network Open, 2020, 3, e203032.	5.9	12
797	Natural language processing for the assessment of cardiovascular disease comorbidities: The <scp>cardioâ€Canary</scp> comorbidity project. Clinical Cardiology, 2021, 44, 1296-1304.	1.8	12
798	Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacement. EuroIntervention, 2019, 15, 155-163.	3.2	12
799	The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. European Heart Journal, 2021, 42, 4865-4866.	2.2	12
800	Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 921.	7.4	11
801	Are All Clinical Trial Sites Created Equal?. Journal of the American College of Cardiology, 2013, 61, 580-581.	2.8	11
802	Hospital patterns of medical management strategy use for patients with nonâ€ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. American Heart Journal, 2014, 167, 355-362.e3.	2.7	11
803	Risk of intracranial hemorrhage after carotid artery stenting versus endarterectomy: a population-based study. Journal of Neurosurgery, 2018, 129, 1522-1529.	1.6	11
804	30-Day Readmissions After EndovascularâThrombectomy for AcuteâIschemic Stroke. JACC: Cardiovascular Interventions, 2018, 11, 2414-2424.	2.9	11
805	Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo. Clinical Immunology, 2018, 194, 26-33.	3.2	11
806	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke, 2019, 14, 270-281.	5.9	11
807	Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. Heart Lung and Circulation, 2019, 28, 939-945.	0.4	11
808	Reply. Journal of the American College of Cardiology, 2019, 74, 1849-1850.	2.8	11
809	Frequency of 30â€day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheterization and Cardiovascular Interventions, 2019, 94, E67-E77.	1.7	11
810	Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. Journal of Thrombosis and Thrombolysis, 2020, 49, 337-343.	2.1	11

#	ARTICLE	IF	CITATIONS
811	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.	2.8	11
812	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). <i>American Heart Journal</i> , 2021, 235, 54-64.	2.7	11
813	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	5.9	11
814	Ticagrelor for patients with acute coronary syndromes: PLATonic affair or lasting SWEDEHEART?. <i>European Heart Journal</i> , 2016, 37, 3343-3346.	2.2	10
815	Fractional Flow Reserve in Serial Coronary Artery Stenoses. <i>JAMA Cardiology</i> , 2016, 1, 359.	6.1	10
816	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	10
817	The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2017, 2, 713.	6.1	10
818	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 875-883.	1.8	10
819	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	2.9	10
820	Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. <i>Clinical Cardiology</i> , 2017, 40, 732-739.	1.8	10
821	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017, 188, 156-166.	2.7	10
822	Rationale and design of the Drug-eluting Stents vs Bare-metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. <i>Clinical Cardiology</i> , 2017, 40, 946-954.	1.8	10
823	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 359-361.	1.6	10
824	Role of Invasive Functional Assessment in Surgical Revascularization of Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 1731-1739.	1.6	10
825	Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Nonranked Hospitals in the United States. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 342-350.	2.9	10
826	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	1.7	10
827	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	3.9	10
828	Targeting RNA to lower triglycerides: long strides from short molecules. <i>European Heart Journal</i> , 2019, 40, 2797-2800.	2.2	10

#	ARTICLE	IF	CITATIONS
829	Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 1497-1503.	2.0	10
830	Catheter Ablation for Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1255.	7.4	10
831	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2517-2521.	2.8	10
832	Pregnancy as a Cardiac Stress Test. <i>Journal of the American College of Cardiology</i> , 2020, 76, 68-71.	2.8	10
833	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 765.	6.1	10
834	Association of inflammatory disease and long-term outcomes among young adults with myocardial infarction: the Mass General Brigham YOUNG-MI Registry. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 352-359.	1.8	10
835	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. <i>Cardiology Clinics</i> , 2021, 39, 335-351.	2.2	10
836	Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery. <i>Current Opinion in Cardiology</i> , 2021, 36, 172-178.	1.8	10
837	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. <i>American Heart Journal</i> , 2022, 244, 135-148.	2.7	10
838	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, e27-e29.	8.6	10
839	The early reduction of left ventricular mass after sleeve gastrectomy depends on the fall of branched-chain amino acid circulating levels. <i>EBioMedicine</i> , 2022, 76, 103864.	6.1	10
840	Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 398-411.	1.6	10
841	Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial. <i>American Heart Journal</i> , 2015, 169, 132-141.e2.	2.7	9
842	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017, 241, 423-429.	1.7	9
843	First-Generation Bioresorbable Vascular Scaffolds. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3067-3069.	2.8	9
844	Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis. <i>Structural Heart</i> , 2018, 2, 223-228.	0.6	9
845	FFR-guided multivessel stenting reduces urgent revascularization compared with infarct-related artery only stenting in ST-elevation myocardial infarction: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 252, 63-67.	1.7	9
846	Effectiveness and Safety of Transcatheter Aortic Valve Implantation for Aortic Stenosis in Patients With "Porcelain" Aorta. <i>American Journal of Cardiology</i> , 2018, 121, 62-68.	1.6	9



#	ARTICLE	IF	CITATIONS
847	Design and rationale of the North Indian STâ€Segment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019, 42, 1140-1146.	1.8	9
848	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in AtrialâFibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	2.9	9
849	De-Escalation of Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 153-159.	2.0	9
850	Meta-Analysis of Transcatheter Aortic Valve Replacement in Low-Risk Patients. <i>American Journal of Medicine</i> , 2020, 133, e38-e41.	1.5	9
851	Incidental Imaging Findings in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 603.	7.4	9
852	Closing Gaps in Essential Chest Pain Care Through Accreditation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2478-2482.	2.8	9
853	Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals. <i>JAMA Network Open</i> , 2020, 3, e203082.	5.9	9
854	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1332.	7.4	9
855	Trends in Cerebral Embolic Protection Device Use and Association With Stroke Following Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 152, 106-112.	1.6	9
856	What Do US Physicians and Patients Think About LipidâLowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e020893.	3.7	9
857	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. <i>International Journal of Cardiology</i> , 2021, 340, 96-104.	1.7	9
858	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. <i>European Heart Journal Supplements</i> , 2020, 22, J54-J64.	0.1	9
859	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. <i>European Cardiology Review</i> , 2021, 16, e40.	2.2	9
860	Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 383-390.	4.0	9
861	Emerging Transcatheter Options for Tricuspid Regurgitation. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 13, 120.	1.0	9
862	Association Between Endovascular Therapy Time to Treatment and Outcomes in Patients With Basilar Artery Occlusion. <i>Circulation</i> , 2022, 145, 896-905.	1.6	9
863	Is It CostâEffective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. <i>Cardiovascular Therapeutics</i> , 2013, 31, 45-52.	2.5	8
864	Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. <i>Annals of Internal Medicine</i> , 2017, 167, 555.	3.9	8

#	ARTICLE	IF	CITATIONS
865	Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 25-37.	0.4	8
866	Long-Term Outcomes of Post-Operative Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 749-751.	2.8	8
867	12 months of DAPT after acute coronary syndrome still beats 6 months. <i>Lancet, The</i> , 2018, 391, 1240-1242.	13.7	8
868	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	3.7	8
869	The perils of polyvascular disease in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 914-916.	11.4	8
870	Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. <i>American Heart Journal</i> , 2019, 213, 47-56.	2.7	8
871	Arterial Inflammation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1383-1385.	2.8	8
872	Comparison of Sex-Based Differences in Home or Nonhome Discharge Utilization of Rehabilitative Services and Outcomes Following Transcatheter Aortic Valve Implantation in the United States. <i>American Journal of Cardiology</i> , 2019, 123, 1983-1991.	1.6	8
873	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	2.9	8
874	Meta-analysis Comparing Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction and Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2019, 123, 218-226.	1.6	8
875	Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. <i>European Heart Journal Supplements</i> , 2020, 22, J1-J2.	0.1	8
876	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e12-e14.	1.8	8
877	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	10.9	8
878	Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1240-1248.	1.7	8
879	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	3.0	8
880	Association Between Omega-3 Fatty Acid Levels and Risk for Incident Major Bleeding Events and Atrial Fibrillation: MESA. <i>Journal of the American Heart Association</i> , 2021, 10, e021431.	3.7	8
881	Target: Stroke Was Associated With Faster Intravenous Thrombolysis and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007150.	2.2	8
882	Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre. <i>EuroIntervention</i> , 2018, 14, e333-e335.	3.2	8

#	ARTICLE	IF	CITATIONS
883	Vascular repair and regeneration in cardiometabolic diseases. <i>European Heart Journal</i> , 2022, 43, 450-459.	2.2	8
884	EMPEROR-Preserved: A promise fulfilled. <i>Cell Metabolism</i> , 2021, 33, 2099-2103.	16.2	8
885	Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. <i>Atherosclerosis</i> , 2022, 353, 11-19.	0.8	8
886	Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. <i>American Journal of Emergency Medicine</i> , 2010, 28, 440-444.	1.6	7
887	Aspirin and proton-pump inhibitors: interpreting the interplay. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 20-22.	3.0	7
888	Overview of Coronary Heart Disease Risk Initiatives in South Asia. <i>Current Atherosclerosis Reports</i> , 2017, 19, 25.	4.8	7
889	What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?. <i>JAMA Cardiology</i> , 2017, 2, 1061.	6.1	7
890	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
891	Optimizing the Use of Cangrelor in the Real World. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 5-16.	2.2	7
892	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	1.0	7
893	Fluorodeoxyglucose Uptake in Atheroma. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1233-1236.	2.8	7
894	The relation between ABO blood types and clinical and platelet function parameters in patients who underwent percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2019, 30, 51-58.	0.7	7
895	COMPASS for Vascular Surgeons. <i>Current Opinion in Cardiology</i> , 2019, 34, 178-184.	1.8	7
896	Frequency of 30-Day Readmission and Its Causes After Endovascular Aneurysm Intervention of Abdominal Aortic Aneurysm (from the Nationwide Readmission Database). <i>American Journal of Cardiology</i> , 2019, 123, 986-994.	1.6	7
897	Anticoagulation Following TAVR. <i>Journal of the American College of Cardiology</i> , 2019, 73, 22-28.	2.8	7
898	Interventions for Secondary Mitral Regurgitation in Patients With Heart Failure: A Network Meta-Analysis of Randomized Controlled Comparisons of Surgery, Medical Therapy and Transcatheter Intervention. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 155-163.	0.8	7
899	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. <i>Clinical Cardiology</i> , 2020, 43, 1209-1215.	1.8	7
900	Necessity of 45-Day Transesophageal Echocardiography After the WATCHMAN Procedure Amid the COVID-19 Pandemic. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2461-2462.	5.3	7

901	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. <i>Atherosclerosis</i> , 2020, 305, 34-41.	0.8	7
902	Self-treatment for acute coronary syndrome: why not?. <i>European Heart Journal</i> , 2020, 41, 2144-2145.	2.2	7
903	Hospital Readmission in Patients With Spontaneous Coronary Artery Dissection. <i>American Journal of Cardiology</i> , 2021, 151, 39-44.	1.6	7
904	Generalizability of DAPA-CKD to the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007875.	2.2	7
905	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020446.	3.7	7
906	Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 31-42.	2.4	7
907	Same-day discharge after transcatheter mitral valve repair using MitraClip in a tertiary community hospital: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab397.	0.6	7
908	Long-Term Evaluation of the Effects of Acclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2018, 5, 5-15.	0.7	7
909	Predictive value of high sensitivity C-reactive protein in the diagnosis and outcomes of acute aortic syndromes. <i>Heart Asia</i> , 2010, 2, 136-9.	1.1	7
910	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121007979.	2.2	7
911	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. <i>European Heart Journal</i> , 2022, 43, 263-270.	2.2	7
912	Generalizability of FIGARO-CKD and FIDELIO-CKD Trial Criteria to the US Population Eligible for Finerenone. <i>Journal of the American Heart Association</i> , 2022, 11, e025079.	3.7	7
913	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. <i>Journal of Clinical Lipidology</i> , 2022, 16, 389-402.	1.5	7
914	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	1.8	7
915	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	2.2	7
916	Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 182-183.	3.3	6
917	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	6
918	Treatment with w-3 fatty acids reduces serum C-reactive protein concentration. <i>Clinical Lipidology</i> , 2011, 6, 723-729.	0.4	6

#	ARTICLE	IF	CITATIONS
919	Explaining Unexplained Dyspnea. Circulation, 2014, 130, 2057-2066.	1.6	6
920	Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data. International Journal of Cardiology, 2014, 175, 72-77.	1.7	6
921	<scp>Frequency</scp> and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction. Clinical Cardiology, 2016, 39, 399-405.	1.8	6
922	â€œOff-Hoursâ€•Versus â€œOn-Hoursâ€•Presentation in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2385-2387.	2.8	6
923	Time-honored treatments for the initial management of acute coronary syndromes: Challenging the status quo. Trends in Cardiovascular Medicine, 2017, 27, 483-491.	4.9	6
924	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	6
925	The Timing of P2Y <sub>12</sub> Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?. Progress in Cardiovascular Diseases, 2018, 60, 471-477.	3.1	6
926	Comparison of Survival After In-Hospital Cardiac Arrest in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2018, 121, 671-677.	1.6	6
927	Aortic Valve Replacement in an Era of Rapid Innovation. Journal of the American College of Cardiology, 2018, 71, 1413-1416.	2.8	6
928	Electronic health records and outpatient cardiovascular disease care delivery: Insights from the American College of Cardiologyâ€™s PINNACLE India Quality Improvement Program (PIQIP). Indian Heart Journal, 2018, 70, 750-752.	0.5	6
929	Aspirinâ€”still the GLOBAL LEADER in antiplatelet therapy. Lancet, The, 2018, 392, 896-897.	13.7	6
930	Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United Statesâ†. American Journal of Cardiology, 2019, 123, 1187-1189.	1.6	6
931	Temporal Trends and Outcomes of Transcatheter Mitral Valve Repair and Surgical Mitral Valve Intervention in Patients With Prior CABG. JACC: Cardiovascular Interventions, 2019, 12, 2445-2447.	2.9	6
932	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. International Journal of Cardiology, 2019, 278, 217-222.	1.7	6
933	Linking Spontaneous Coronary Artery Dissection, Cervical Artery Dissection, and Fibromuscular Dysplasia. Journal of the American College of Cardiology, 2019, 73, 67-69.	2.8	6
934	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 309-317.	1.0	6
935	On the Pearls and Perils of Sub-Subspecialization. American Journal of Medicine, 2020, 133, 158-159.	1.5	6
936	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2020, 75, 448-451.	2.8	6

#	ARTICLE	IF	CITATIONS
937	Impact of chronic kidney disease on in-hospital outcomes and readmission rate after edge-to-edge transcatheter mitral valve repair. Catheterization and Cardiovascular Interventions, 2021, 97, E569-E579.	1.7	6
938	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6
939	Transmitting Device Identifiers of Implants From the Point of Care to Insurers: A Demonstration Project. Journal of Patient Safety, 2021, 17, 223-230.	1.7	6
940	Patient perspectives on the need for implanted device information: Implications for a post-procedural communication framework. Health Expectations, 2021, 24, 1391-1402.	2.6	6
941	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	1.7	6
942	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Progress in Cardiovascular Diseases, 2021, 68, 97-98.	3.1	6
943	Meta-Analysis of Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2021, 157, 8-14.	1.6	6
944	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). PLoS ONE, 2021, 16, e0259372.	2.5	6
945	Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. Journal of Invasive Cardiology, 2003, 15 Suppl B, 3B-9B; discussion 9B-10B.	0.4	6
946	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, .	0.7	6
947	Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. JAMA Internal Medicine, 2022, 182, 559.	5.1	6
948	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	3.0	6
949	Percutaneous coronary intervention in nonagenarians: Age before beauty?. Catheterization and Cardiovascular Interventions, 2008, 71, 531-532.	1.7	5
950	Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. Thrombosis Research, 2014, 134, 96-104.	1.7	5
951	Conductance sizing balloon for measurement of peripheral artery minimal stent area. Journal of Vascular Surgery, 2014, 60, 759-766.	1.1	5
952	Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program. American Heart Journal, 2014, 168, 340-345.	2.7	5
953	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. European Heart Journal, 2015, 36, 1424-1427.	2.2	5
954	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. Clinical Cardiology, 2016, 39, 497-506.	1.8	5



#	ARTICLE	IF	CITATIONS
955	Do Acute Myocardial Infarction and Heart Failure Readmissions Flagged as Potentially Preventable by the 3M Potentially Preventable Readmissions Software Have More Process-of-Care Problems? Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 532-541.	2.2	5
956	Simultaneous Platelet P2Y <sub>12</sub> and P2Y <sub>1</sub> ADP Receptor Blockade. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 427-428.	2.4	5
957	Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. Diabetes, Obesity and Metabolism, 2017, 19, 1045-1050.	4.4	5
958	Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Circulation, 2018, 137, 2427-2429.	1.6	5
959	LumenRECON Guidewire. Circulation: Cardiovascular Interventions, 2018, 11, e005333.	3.9	5
960	Advances in atherosclerosis, atrial fibrillation, and valvular disease. Nature Reviews Cardiology, 2018, 15, 71-72.	13.7	5
961	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheterization and Cardiovascular Interventions, 2018, 92, E348-E355.	1.7	5
962	UDI2Claims. Journal of Patient Safety, 2018, Publish Ahead of Print, e708-e715.	1.7	5
963	Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?. Circulation, 2018, 138, 858-860.	1.6	5
964	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	3.2	5
965	Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2019, 94, 181-186.	1.7	5
966	Trends in the Use of Short-Term Mechanical Circulatory Support in the United States – An Analysis of the 2012 – 2015 National Inpatient Sample. Structural Heart, 2019, 3, 499-506.	0.6	5
967	A New Dimension in the Relationship Between Procedural Volumes and Quality. Circulation, 2019, 139, 473-476.	1.6	5
968	Wake Forest University long-term follow-up of type 2 myocardial infarction: The WakeUp T2MI Registry. Clinical Cardiology, 2019, 42, 592-604.	1.8	5
969	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). American Journal of Cardiology, 2019, 123, 618-626.	1.6	5
970	Insights From Autopsies. JACC: Cardiovascular Imaging, 2019, 12, 146-148.	5.3	5
971	Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine, 2019, 20, 744-751.	0.8	5
972	Prevalence, Presentation, and Associated Conditions of Patients With Fibromuscular Dysplasia. American Journal of Cardiology, 2019, 123, 1169-1172.	1.6	5

#	ARTICLE	IF	CITATIONS
973	Trends in Costs and Risk Factors of 30-Day Readmissions for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 137, 89-96.	1.6	5
974	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. Journal of the American College of Cardiology, 2020, 76, 2907-2910.	2.8	5
975	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC: Cardiovascular Interventions, 2020, 13, 1012-1014.	2.9	5
976	Self-employment and cardiovascular risk in the US general population. International Journal of Cardiology: Hypertension, 2020, 6, 100035.	2.2	5
977	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006582.	2.2	5
978	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC: Cardiovascular Interventions, 2021, 14, 768-780.	2.9	5
979	The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl. European Heart Journal, 2021, 42, 3025-3026.	2.2	5
980	Mapping and quantification of the twitter footprint of cardiologists. European Heart Journal Digital Health, 2021, 2, 374-378.	1.7	5
981	Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. American Journal of Cardiovascular Drugs, 2022, 22, 93-104.	2.2	5
982	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 150, 15-23.	1.6	5
983	Meta-Analysis of Contemporary Trials of Omega-3 Fatty Acids Containing Both Eicosapentaenoic and Docosahexaenoic Acids. EClinicalMedicine, 2021, 39, 101110.	7.1	5
984	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure. JACC: CardioOncology, 2020, 2, 710-718.	4.0	5
985	Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East. Heart Asia, 2011, 3, 77-81.	1.1	5
986	Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States. Journal of the American Heart Association, 2022, 11, e023110.	3.7	5
987	Asymptomatic acute inferior ST elevation myocardial infarction from thermal injury complicating radiofrequency ablation for atrioventricular re-entrant tachycardia. Journal of Invasive Cardiology, 2004, 16, 504-5.	0.4	5
988	Medical management of peripheral artery disease in diabetes mellitus. European Heart Journal, 2015, 36, 1494-5.	2.2	5
989	Left circumflex artery injury following surgical mitral valve replacement: a case report. European Heart Journal - Case Reports, 2021, 5, ytab464.	0.6	5
990	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, E12-E14.	3.0	5

#	ARTICLE	IF	CITATIONS
991	Passive longitudinal weight and cardiopulmonary monitoring in the home bed. Scientific Reports, 2021, 11, 24376.	3.3	5
992	Cardiovascular Safety Assessment in Cancer Drug Development. Journal of the American Heart Association, 2021, 10, e024033.	3.7	5
993	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention, 2022, 18, e292-e302.	3.2	5
994	Same-Day Discharge After Transcatheter Aortic Valve Implantation: Insights from the Nationwide Readmission Database 2015 to 2019. Journal of the American Heart Association, 2022, 11, .	3.7	5
995	Identification of and Management Approaches for the High-Risk Patient. American Journal of Cardiology, 2006, 98, S22-S29.	1.6	4
996	Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 252-253.	3.3	4
997	Clopidogrel resistance “A clear problem with an unclear solution. Indian Heart Journal, 2012, 64, 353-355.	0.5	4
998	Myocardial Bridging in a Man With Non-ST-Elevation Myocardial Infarction. Circulation, 2015, 131, e373-4.	1.6	4
999	Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. International Journal of Cardiology, 2015, 189, 141-147.	1.7	4
1000	Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System. Journal of the American Heart Association, 2016, 5, .	3.7	4
1001	Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. International Journal of Cardiology, 2017, 243, 95-97.	1.7	4
1002	Risks of Overinterpreting Interim Data. Circulation, 2018, 137, 206-209.	1.6	4
1003	Oral Antidiabetic Agents and Cardiovascular Outcomes. Current Problems in Cardiology, 2018, 43, 111-126.	2.4	4
1004	Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis. Cardiology in Review, 2018, 26, 277-286.	1.4	4
1005	Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?. Current Cardiology Reports, 2018, 20, 110.	2.9	4
1006	Fractional Flow Reserve Measurement for the Physiological Assessment of Coronary Artery Stenosis Severity. JAMA - Journal of the American Medical Association, 2018, 320, 1275.	7.4	4
1007	Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. Journal of the American College of Cardiology, 2018, 71, 2727-2730.	2.8	4
1008	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology, 2019, 42, 797-805.	1.8	4

#	ARTICLE	IF	CITATIONS
1009	Trends in elective and ruptured abdominal aortic aneurysm repair by practice setting in Ontario, Canada, from 2003 to 2016: a population-based time-series analysis. CMAJ Open, 2019, 7, E379-E384.	2.4	4
1010	A paradoxical relationship between hemoglobin A1C and in-hospital mortality in intracerebral hemorrhage patients. Heliyon, 2019, 5, e01659.	3.2	4
1011	Meta-analysis of Percutaneous Coronary Intervention Versus Medical Therapy in the Treatment of Coronary Chronic Total Occlusion. American Journal of Cardiology, 2019, 123, 2060-2062.	1.6	4
1012	Percutaneous Versus Surgical Pulmonic Valve Implantation for Right Ventricular Outflow Tract Dysfunction. Cardiovascular Revascularization Medicine, 2019, 20, 553-558.	0.8	4
1013	Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting With Transient Ischemic Attack. American Journal of Cardiology, 2019, 123, 1083-1095.	1.6	4
1014	Predictors of Hospital Cost After Transcatheter Aortic Valve Implantation in the United States: From the Nationwide Inpatient Sample Database. American Journal of Cardiology, 2019, 123, 1142-1148.	1.6	4
1015	Long-term predictive value of stroke volume index obtained from right heart catheterization: Insights from the veterans affairs clinical assessment, reporting, and tracking program. Clinical Cardiology, 2020, 43, 1126-1132.	1.8	4
1016	Applying to Medical School in the COVID-19 Era. Mayo Clinic Proceedings, 2020, 95, 2317-2319.	3.0	4
1017	Association Between the Framingham Risk Score and Carotid Artery Intima-Media Thickness in Patients With Human Immunodeficiency Virus. American Journal of Cardiology, 2020, 127, 156-162.	1.6	4
1018	Early Post-Percutaneous Coronary Intervention Chest Pain: A Nationwide Survey on Interventional Cardiologists' Perspective. Cardiovascular Revascularization Medicine, 2020, 21, 1517-1522.	0.8	4
1019	Impella in Cardiogenic Shock: Is it Time to Hit the Break?. Shock, 2021, 55, 693-694.	2.1	4
1020	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	2.1	4
1021	Should patients stop taking aspirin for primary prevention?. Cleveland Clinic Journal of Medicine, 2015, 82, 91-96.	1.3	4
1022	Time to Remove the Left Atrial Appendage at Surgery: LAAOS III in Perspective. Circulation, 2021, 144, 1088-1090.	1.6	4
1023	Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 68-81.	2.5	4
1024	Innovation in intervention. Progress in Cardiovascular Diseases, 2021, 69, 1-2.	3.1	4
1025	In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). American Journal of Cardiology, 2022, 162, 24-30.	1.6	4
1026	Impact of sex on outcomes of percutaneous coronary intervention for chronic total occlusion: A meta-analysis. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	4

#	ARTICLE	IF	CITATIONS
1027	Abstract 15389: Effect of Icosapent Ethyl on Changes in Coronary Plaque Characteristics at 9 Months in Patients With Elevated Triglycerides on Statin Therapy: Insights From EVAPORATE. Circulation, 2020, 142, .	1.6	4
1028	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
1029	Embolization—a pathological mechanism in renal artery stenosis. Journal of Invasive Cardiology, 2004, 16, 196-7.	0.4	4
1030	Secular Trends in Prevalence of Heart Failure Diagnosis over 20 Years (from the US NHANES). American Journal of Cardiology, 2022, , .	1.6	4
1031	Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trial. American Heart Journal, 2022, 248, 21-34.	2.7	4
1032	Guideline based eligibility for primary prevention statin therapy “ Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). Journal of Clinical Lipidology, 2021, , .	1.5	4
1033	Machine learning based model for risk prediction after ST-Elevation myocardial infarction: Insights from the North India ST elevation myocardial infarction (NORIN-STEMI) registry. International Journal of Cardiology, 2022, 362, 6-13.	1.7	4
1034	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	1.7	4
1035	The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. American Journal of Preventive Cardiology, 2022, 10, 100345.	3.0	4
1036	Cangrelor Use Patterns and Transition to Oral P2Y <sub>12</sub> Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. Journal of the American Heart Association, 2022, 11, .	3.7	4
1037	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	1.7	4
1038	Response to Letter Regarding Article, “Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk” Circulation, 2009, 119, .	1.6	3
1039	Conduits in Coronary Artery Bypass Grafting. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 273-279.	0.6	3
1040	Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	3
1041	Trends in Palliative Care Use in Elderly Men and Women With Severe Heart Failure in the United States”Reply. JAMA Cardiology, 2017, 2, 344.	6.1	3
1042	Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease. Heart, 2018, 104, 1144-1147.	2.9	3
1043	Biomarkers enter the world of peripheral artery disease. European Heart Journal, 2018, 39, 2420-2422.	2.2	3
1044	Relationship of Hospital Teaching Status with In-Hospital Outcomes for ST-Segment Elevation Myocardial Infarction. American Journal of Medicine, 2018, 131, 260-268.e1.	1.5	3

#	ARTICLE	IF	CITATIONS
1045	Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?. Journal of the American College of Cardiology, 2018, 72, 3270-3273.	2.8	3
1046	Coronary Bypass Surgery for Diabetes and Multivessel Disease. Journal of the American College of Cardiology, 2018, 72, 2838-2840.	2.8	3
1047	Meta-Analysis Evaluating the Effect of Left Coronary Dominance on Outcomes After Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 2026-2034.	1.6	3
1048	The impact of randomized trial results on abdominal aortic aneurysm repair rates from 2003 to 2016: A population-based time-series analysis. Vascular, 2019, 27, 417-426.	0.9	3
1049	Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis. Journal of Thrombosis and Thrombolysis, 2019, 48, 11-13.	2.1	3
1050	Outcomes and Resource Utilization for Nonelective Versus Elective Transcatheter Mitral Valve Repair. American Journal of Cardiology, 2019, 123, 1889-1891.	1.6	3
1051	Cardiometabolic risk reduction after metabolic surgery. Current Opinion in Cardiology, 2019, 34, 663-672.	1.8	3
1052	More Evidence That We Could All Use a Good Night's Sleep. Journal of the American College of Cardiology, 2019, 73, 145-147.	2.8	3
1053	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 62-71.	4.0	3
1054	Comparison of Incidence and Outcomes of Cardiogenic Shock Complicating Posterior (Inferior) Versus Anterior ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 125, 1013-1019.	1.6	3
1055	An Optimized Approach for Transfemoral Transcatheter Aortic Valve Implantation: A Comprehensive Review and Current Evidence. Cardiovascular Revascularization Medicine, 2020, 21, 1034-1040.	0.8	3
1056	Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more. Journal of Thrombosis and Thrombolysis, 2020, 49, 321-324.	2.1	3
1057	Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts. Indian Heart Journal, 2020, 72, 337-344.	0.5	3
1058	A questionnaire survey for improving awareness of rheumatic heart disease among school-aged children in India. Indian Heart Journal, 2020, 72, 410-415.	0.5	3
1059	Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. International Journal of Cardiology, 2020, 321, 88-94.	1.7	3
1060	Response by Bhatt et al to Letter Regarding Article, "REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States". Circulation, 2020, 141, e834-e835.	1.6	3
1061	Complete revascularization for patients with multivessel coronary artery disease and ST-segment elevation myocardial infarction after the COMPLETE trial: A meta-analysis of randomized controlled trials. IJC Heart and Vasculature, 2020, 29, 100549.	1.1	3
1062	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	1.7	3



#	ARTICLE	IF	CITATIONS
1063	Underdiagnosis of Isolated Systolic and Isolated Diastolic Hypertension. American Journal of Cardiology, 2021, 141, 56-61.	1.6	3
1064	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e38-e40.	3.0	3
1065	Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology, 2021, 6, 384-394.	3.3	3
1066	To stent or not to stent? Treating angina after ISCHEMIAâ€™ introduction. European Heart Journal, 2021, 42, 1387-1400.	2.2	3
1067	Reconfiguring the Cardiovascular Clinical Trial Enterprise in the United States. JAMA Network Open, 2021, 4, e2118176.	5.9	3
1068	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. American Heart Journal, 2022, 243, 54-65.	2.7	3
1069	Interpreting the COURAGE trial. Is medical therapy as good as PCI in stable angina? Two views.. Cleveland Clinic Journal of Medicine, 2007, 74, 618-618.	1.3	3
1070	Serum Potassium and Mortality in High-Risk Patients: SPRINT. Hypertension, 2021, 78, 1586-1594.	2.7	3
1071	In NSTEMI, are patients without SMuRFs real?. European Journal of Preventive Cardiology, 2022, 29, 1081-1083.	1.8	3
1072	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. Clinical Cardiology, 2022, , .	1.8	3
1073	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 1267-1277.	1.7	3
1074	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. Current Cardiology Reports, 2022, 24, 277-293.	2.9	3
1075	Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19: A Danish nationwide registry-based cohort study. American Heart Journal Plus, 2022, 14, 100131.	0.6	3
1076	Evaluating the evaluators - Developing evidence of quality oversight effectiveness for clinical trial monitoring: Source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high risk errors. Contemporary Clinical Trials, 2022, 117, 106764.	1.8	3
1077	Clopidogrel Bisulfate In ST-Segment Elevation Myocardial Infarction. American Journal of Cardiovascular Drugs, 2006, 6, 415-416.	2.2	2
1078	Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology, 2011, 27, 222-231.	1.7	2
1079	Dual Antiplatelet Therapy After Stent Implantationâ€™Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1446.	7.4	2
1080	Response by Hess et al to Letter Regarding Article, â€™Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Programâ€™. Circulation, 2017, 135, e22-e23.	1.6	2

#	ARTICLE	IF	CITATIONS
1081	My Approach to the patient with CAD and aspirin resistance. Trends in Cardiovascular Medicine, 2017, 27, 518-519.	4.9	2
1082	Predicting Risk in ACS. Journal of the American College of Cardiology, 2017, 70, 1858-1860.	2.8	2
1083	Segmental Arterial Mediolytic: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis. American Journal of Medicine, 2018, 131, e231-e234.	1.5	2
1084	Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. European Heart Journal Supplements, 2018, 20, B21-B28.	0.1	2
1085	Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". Circulation, 2018, 138, 2306-2307.	1.6	2
1086	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). American Journal of Cardiology, 2018, 122, 1322-1329.	1.6	2
1087	A LEADER in the management of type 2 diabetes and cardiorenal disease. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 978-984.	0.8	2
1088	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 238-240.	2.8	2
1089	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	1.7	2
1090	A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1517-1528.	0.9	2
1091	Federal judge invalidates icosapent ethyl patents "but on the basis of a common statistical mistake. Nature Biotechnology, 2020, 38, 939-941.	17.5	2
1092	Long-Term Outcomes With Drug-Eluting Stents or Coronary Artery Bypass Surgery for Unprotected Left Main Coronary Disease: A Meta-Analysis and Trial Sequential Analysis of Randomized Trials. American Journal of Cardiology, 2020, 126, 111-112.	1.6	2
1093	Management of acute myocardial injury in patients with confirmed or suspected COVID-19. Atherosclerosis, 2020, 305, 58-60.	0.8	2
1094	Continued Evolution of Renal Artery Denervation for Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 485-487.	2.9	2
1095	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
1096	Liraglutide to Improve coronary haemodynamics during Exercise stress (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetology and Metabolic Syndrome, 2021, 13, 17.	2.7	2
1097	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	2.1	2
1098	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a DUAL) Tj ETQq0 0 Q ggBT /Overlock 10 T Cardiology, 2021, 44, 1002-1010.	1.8	2

#	ARTICLE	IF	CITATIONS
1099	Long-Term Outcomes Following Myocardial Infarction in Young Adult Survivors of Hodgkin Lymphoma. JACC: CardioOncology, 2021, 3, 319-321.	4.0	2
1100	Same-Day Discharge After Elective PCI. JACC: Cardiovascular Interventions, 2021, 14, 1667-1669.	2.9	2
1101	Adaptive Trials in Cardiology: Some Considerations and Examples. Canadian Journal of Cardiology, 2021, 37, 1428-1437.	1.7	2
1102	Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure. US Cardiology Review, 2020, 13, 83-87.	0.5	2
1103	Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 2021, 52, e777-e781.	2.0	2
1104	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. Cleveland Clinic Journal of Medicine, 2021, 88, 601-606.	1.3	2
1105	Dual pathway inhibition in atherothrombosis prevention: yes, now we can!. Minerva Cardiology and Angiology, 2021, , .	0.7	2
1106	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circulation: Cardiovascular Interventions, 2021, , CIRCINTERVENTIONS120011035.	3.9	2
1107	Abstract 14687: Achieved Eicosapentaenoic Acid (EPA) Levels Predicts Regression of Coronary Plaque Volumes by Coronary Computed Tomography Angiography (CCTA) in the EVAPORATE Trial. Circulation, 2020, 142, .	1.6	2
1108	Socioeconomic disparities in healthcare utilization for atherosclerotic cardiovascular disease. American Heart Journal, 2022, 246, 161-165.	2.7	2
1109	Geriatric and Palliative Care Specialists as Valued Members of the Multidisciplinary Heart Team. American Journal of Medicine, 2022, 135, 810-812.	1.5	2
1110	Heparin in peripheral vascular intervention--time for a change?. Journal of Invasive Cardiology, 2003, 15, 249-50.	0.4	2
1111	Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion. Journal of Invasive Cardiology, 2005, 17, 283-7.	0.4	2
1112	Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation. Scientific Reports, 2022, 12, 4377.	3.3	2
1113	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	2
1114	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin Following WATCHMAN in High-Risk Patients. , 2022, , 100042.		2
1115	EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis. JACC: Cardiovascular Imaging, 2022, , .	5.3	2
1116	Response to Letter Regarding Article, "Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention? Meta-Analysis of Randomized Trials". Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	1

#	ARTICLE	IF	CITATIONS
1117	Expanding the Boundaries of Heart Failure Care with Interventional and Device Therapy. Heart Failure Clinics, 2015, 11, xiii.	2.1	1
1118	Highlights from the 65th American College of Cardiology Annual Scientific Session (ACC 2016). European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 142-144.	3.0	1
1119	Concurrent Lower Gastrointestinal Bleeding Risk and Myocardial Ischemic Risk: Resume Aspirin or Not?. Gastroenterology, 2016, 151, 222-225.	1.3	1
1120	Mechanical Thrombectomy and Functional Outcomes After Stroke. JAMA - Journal of the American Medical Association, 2016, 315, 1791.	7.4	1
1121	Future prospects for renal artery denervation. Journal of the American Society of Hypertension, 2016, 10, 393-395.	2.3	1
1122	Transcatheter and Doppler waveform correlation in transcatheter aortic valve replacement. Open Heart, 2018, 5, e000728.	2.3	1
1123	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. International Journal of Cardiology, 2018, 252, 214-215.	1.7	1
1124	Art and Science in Registry Studies of Anemia and Myocardial Infarction. Circulation: Cardiovascular Interventions, 2018, 11, e007571.	3.9	1
1125	Thin to Ultrathin. Circulation: Cardiovascular Interventions, 2018, 11, e007407.	3.9	1
1126	Real-world revascularization therapy in heart failure: It's a jungle out there!. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1422-1423.	0.8	1
1127	Endoscopic versus Open Vein-Graft Harvesting for CABG. New England Journal of Medicine, 2019, 380, e43.	27.0	1
1128	One- to 10-Day Versus 11- to 30-Day All-Cause Readmission and Mortality in Older Patients With Heart Failure. American Journal of Cardiology, 2019, 123, 1840-1844.	1.6	1
1129	Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?. Canadian Journal of Cardiology, 2020, 36, 24-26.	1.7	1
1130	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, e35-e37.	3.0	1
1131	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. American Journal of Medicine, 2020, 133, 1302-1312.	1.5	1
1132	Characteristics, results, and reporting of contemporary surgical trials: A systematic review and analysis. International Journal of Surgery Protocols, 2020, 21, 1-4.	1.1	1
1133	Selective Autoreperfusion Provides Substantial Cardioprotection in Swine. JACC Basic To Translational Science, 2020, 5, 267-278.	4.1	1
1134	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	1.6	1

#	ARTICLE	IF	CITATIONS
1135	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovascular Drugs and Therapy, 2021, 35, 533-538.	2.6	1
1136	Letter by Angiolillo et al Regarding Article, “Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial” Circulation, 2021, 143, e795-e796.	1.6	1
1137	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med, 2021, 2, 233-242.	4.4	1
1138	Crossover in COAPT. Journal of the American College of Cardiology, 2021, 77, 1041-1043.	2.8	1
1139	To stent or not to stent? Treating angina after ISCHEMIA—the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease. European Heart Journal, 2021, 42, 1389-1393.	2.2	1
1140	Variation in treatment strategy for NSTEMI: A complex phenomenon. International Journal of Cardiology, 2021, 331, 14-16.	1.7	1
1141	Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coronary Artery Disease, 2022, 33, 98-104.	0.7	1
1142	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
1143	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respiratory Research, 2021, 22, 272.	3.6	1
1144	Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions. Cleveland Clinic Journal of Medicine, 2010, 77, 101-109.	1.3	1
1145	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including) Tj ETQq1 1104784314rgBT /Ove		
1146	Abstract 12509: Initial Reports on the Safety of Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Taking Novel Oral Anticoagulants (NOACs). Circulation, 2015, 132, .	1.6	1
1147	Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD <sup>2</sup> score. Stroke and Vascular Neurology, 2021, 6, 314-318.	3.3	1
1148	Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook. Journal of the American Heart Association, 2021, 10, e023673.	3.7	1
1149	Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
1150	Editorial commentary: Weight loss for cardiovascular disease prevention “is semaglutide the answer?”. Trends in Cardiovascular Medicine, 2023, 33, 167-169.	4.9	1
1151	Abstract WP229: Eicosapentaenoic Acid (EPA) Modulates Expression Of Thrombotic And Metabolic Proteins In Brain Endothelium Following Cytokine Challenge. Stroke, 2022, 53, .	2.0	1
1152	Heads Up! Introducing Wearable Health Technologies in Cardiology. Journal of Invasive Cardiology, 2015, 27, 447.	0.4	1

#	ARTICLE	IF	CITATIONS
1153	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. American Heart Journal, 2022, 249, 23-23.	2.7	1
1154	No Diagnostic Concerns With Cardiovascular Magnetic Resonance Imaging in Patients With Breast Cancer and Breast Implantsâ€”Reply. JAMA Cardiology, 2022, 7, 655.	6.1	1
1155	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	1.6	1
1156	Antiplatelet Therapy in Chronic Coronary Artery Disease. , 0, , 178-195.		0
1157	Response to Letter Regarding Article, â€œSmoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Diseaseâ€• Circulation, 2010, 122, .	1.6	0
1158	Response to Letter Regarding Article â€œClinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attackâ€• Stroke, 2012, 43, .	2.0	0
1159	Adjunctive Pharmacotherapy for Thrombotic Coronary Lesions. Interventional Cardiology Clinics, 2013, 2, 375-387.	0.4	0
1160	Late breaking trials of 2014 in coronary artery disease: Commentary covering <scp>ACC</scp>, Euro<scp>PCR</scp>, <scp>SCAI</scp>, <scp>TCT</scp>, <scp>ESC</scp>, and <scp>AHA</scp>. Catheterization and Cardiovascular Interventions, 2015, 86, 73-79.	1.7	0
1161	Warfarin in patients on haemodialysis with atrial fibrillationâ€”friend or foe?. Nature Reviews Nephrology, 2015, 11, 450-450.	9.6	0
1162	Response by Bagai et al to Letter Regarding Article, â€œIndividualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Interventionâ€• Circulation, 2016, 134, e334-e335.	1.6	0
1163	Letter by Taqueti and Bhatt Regarding Article, â€œImpact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Studyâ€• Circulation, 2017, 135, e864-e865.	1.6	0
1164	Blood pressure and cardiovascular outcomes: a closer look â€” Authors' reply. Lancet, The, 2017, 389, 1296-1297.	13.7	0
1165	A heart within a heart. Catheterization and Cardiovascular Interventions, 2017, 89, 1239-1241.	1.7	0
1166	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetesâ€”Reply. JAMA Cardiology, 2017, 2, 821.	6.1	0
1167	The Wrong Toothpaste and the Painful Burp. American Journal of Medicine, 2017, 130, e19-e20.	1.5	0
1168	Editorial commentary: Novel developments in revascularization for left main coronary artery disease. Trends in Cardiovascular Medicine, 2018, 28, 365-366.	4.9	0
1169	Trends in Carotid Revascularization Procedures. JAMA - Journal of the American Medical Association, 2018, 319, 307.	7.4	0
1170	Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2018, 13, 163-170.	0.9	0



#	ARTICLE	IF	CITATIONS
1171	Public Reporting of Percutaneous Coronary Intervention Outcomes Done Differently—Leading From Washington—Reply. JAMA Cardiology, 2018, 3, 1127.	6.1	0
1172	The Reply. American Journal of Medicine, 2018, 131, e389-e390.	1.5	0
1173	The Reply. American Journal of Medicine, 2018, 131, e263.	1.5	0
1174	Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. Journal of Thrombosis and Thrombolysis, 2018, 46, 134-138.	2.1	0
1175	The Reply. American Journal of Medicine, 2018, 131, e267-e268.	1.5	0
1176	Balloon Predilation in Transcatheter Aortic Valve Replacement with Self-expanding Valves. Structural Heart, 2019, 3, 65-71.	0.6	0
1177	Leadership in Cardiovascular Medicine. European Heart Journal, 2019, 40, 1395-1397.	2.2	0
1178	Response by DeFilippis et al to Letter Regarding Article, “Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction: Partners YOUNG-MI Registry” Circulation, 2019, 139, e996.	1.6	0
1179	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y <sub>12</sub> Inhibitor Pretreatment. Circulation: Cardiovascular Interventions, 2019, 12, e007445.	3.9	0
1180	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
1181	Coronary artery bypass grafting surgery versus percutaneous coronary intervention for coronary artery disease. The Cochrane Library, 2019, , .	2.8	0
1182	Minding the gaps in post-myocardial infarction mortality between Sweden and the UK. Cardiovascular Research, 2020, 116, 9-11.	3.8	0
1183	Reply. JACC: Cardiovascular Interventions, 2020, 13, 2309-2310.	2.9	0
1184	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 128, 113-119.	1.6	0
1185	Differential effect of ticagrelor on irreversible harms in diabetes — Authors' reply. Lancet, The, 2020, 396, 93-94.	13.7	0
1186	The Reply. American Journal of Medicine, 2020, 133, e164-e165.	1.5	0
1187	Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2020, 49, 522-526.	2.1	0
1188	The Emerging Role of Coronary Computed Tomography Angiography in Stable Angina With ISCHEMIA. JACC: Cardiovascular Imaging, 2021, 14, 1394-1397.	5.3	0

#	ARTICLE	IF	CITATIONS
1189	Abstract P384: Outcomes of Endovascular Therapy in Patients With Pre-Stroke Mobility Impairment. Stroke, 2021, 52, .	2.0	0
1190	Is There an Optimal Antiplatelet Strategy after Gastrointestinal Bleeding in Patients with Coronary Artery Disease?. Cardiology, 2021, 146, 668-677.	1.4	0
1191	Efficacy of Acridinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	2.9	0
1192	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. Critical Pathways in Cardiology, 2021, Publish Ahead of Print, 173-178.	0.5	0
1193	Improving Communication of Incidental Imaging Findings. Mayo Clinic Proceedings, 2021, 96, 2753-2756.	3.0	0
1194	Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke, 2021, 52, e725-e728.	2.0	0
1195	A novel technique for invasive aortic valve pressure gradient measurement using a 6â€‰Fr Swan-Ganz catheter: a case series. European Heart Journal - Case Reports, 2021, 5, ytab383.	0.6	0
1196	An international prospective observational registry in subjects at risk of atherothrombotic events. Japanese Journal of Thrombosis and Hemostasis, 2004, 15, 376-382.	0.1	0
1197	Platelet response in practice: Applying new insights and tools for testing and treatment. Cleveland Clinic Journal of Medicine, 2009, 76, S24-S32.	1.3	0
1198	Abstract P108: Cardiovascular Health Awareness and the Effect of an Educational Intervention on School-aged Children in Calcutta, India. Circulation, 2020, 141, .	1.6	0
1199	IgM Antibodies with atheroprotective properties in heart transplants are IgM antiâ€œphosphorylcholine. FASEB Journal, 2020, 34, 1-1.	0.5	0
1200	Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2020, 142, .	1.6	0
1201	Abstract 13214: Underuse of Combination Pharmacotherapy for Management of Dyslipidemia versus Diabetes and Hypertension Among Patients With Atherosclerotic Cardiovascular Disease (ascvd): Insights From the Getting to an Improved Understanding of Low-density Lipoprotein-cholesterol and Dyslipidemia Management (gould) Registry. Circulation, 2020, 142, .	1.6	0
1202	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2020, 142, .	1.6	0
1203	Abstract 15913: Two-year Results of the Getting to an Improved Understanding of Low-density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) Registry of Patients With Atherosclerotic Cardiovascular Disease (ASCVD). Circulation, 2020, 142, .	1.6	0
1204	Abstract 15091: Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT. Circulation, 2020, 142, .	1.6	0
1205	Abstract 14073: Omega-3 Fatty Acid Levels and Risk for Incident Bleeding and Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2020, 142, .	1.6	0
1206	Abstract 15502: Clinical Outcomes in Patients Undergoing Non-cardiac Surgery Within 1 Year of Pci. Circulation, 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
1207	Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes. Circulation, 2020, 142, .	1.6	0
1208	Abstract 16195: Socioeconomic Disadvantage is Associated With Higher Long-Term Cardiovascular Mortality Following Myocardial Infarction: The YOUNG-MI Registry. Circulation, 2020, 142, .	1.6	0
1209	Abstract 15015: Eicosapentaenoic Acid, but Not Docosahexaenoic Acid or a Mixed Omega-3 Fatty Acid Supplement, Inhibits Low-density Lipoprotein Oxidation in a Time-dependent Manner. Circulation, 2020, 142, .	1.6	0
1210	Abstract 16486: Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT. Circulation, 2020, 142, .	1.6	0
1211	Abstract 16749: Prevalence, Predictors, and Prognostic Implications of Left Ventricular Systolic Dysfunction Among Patients With STEMI in India: The Prospective NORIN-STEMI Registry. Circulation, 2020, 142, .	1.6	0
1212	Abstract 14758: Contrasting Effects of Phospholipid Linked Eicosapentaenoic Acid and Arachidonic Acid on Membrane Structure and Stability. Circulation, 2020, 142, .	1.6	0
1213	Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials. Circulation, 2020, 142, .	1.6	0
1214	Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial. Circulation, 2020, 142, .	1.6	0
1215	Abstract 16407: Plasma Omega-3 Fatty Acids Predict Cardiovascular Events Stratified by Coronary Artery Calcium. Circulation, 2020, 142, .	1.6	0
1216	Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus” Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	0
1217	Substantial Impact of Eicosapentaenoic Acid on Cardiovascular Outcomes in the REDUCE-IT Trial. Cardiometabolic Syndrome Journal, 0, 2, .	0.6	0
1218	Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, , .	1.6	0
1219	Abstract WP210: Eicosapentaenoic Acid (EPA) Decreases Cytokine Release And Inflammatory Proteins In Brain Vascular Endothelium During Inflammation. Stroke, 2022, 53, .	2.0	0
1220	Bleeding complications during percutaneous coronary intervention. Journal of Invasive Cardiology, 2004, 16, 24S-29S.	0.4	0
1221	Emboli protection devices. Journal of Invasive Cardiology, 2004, 16, 45S-49S.	0.4	0
1222	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0
1223	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. American Journal of Medicine, 2022, , .	1.5	0
1224	Abstract 10632: Variation in the Association Between Beta Blocker and/or Rasi Use After Discharge and Outcomes in Hfref by Age. Circulation, 2021, 144, .	1.6	0

#	ARTICLE	IF	CITATIONS
1225	Abstract 10868: Risk Factors and Long-Term Outcomes of Cardiogenic Shock in Young Patients with Myocardial Infarction - The Mass General Brigham Young-MI Registry. Circulation, 2021, 144, .	1.6	0
1226	Has Unstable Angina Become a Vestigial of the Past in Clinical Trial Primary Endpoints?. Cardiology, 2022, , .	1.4	0
1227	Abstract 9758: Estimating Cardiovascular and Limb Benefits of Combined Contemporary Risk Reduction Therapies in Patients with Symptomatic Peripheral Artery Disease: An Analysis of Randomized Controlled Trials. Circulation, 2021, 144, .	1.6	0
1228	Cardiovascular meta-analyses: foolâ€™s gold or gold for fools?. European Heart Journal, 0, , .	2.2	0
1229	Costs of Endoscopic vs Open Vein Harvesting for Coronary Artery Bypass Grafting. JAMA Network Open, 2022, 5, e2217686.	5.9	0